Generated by All in One SEO v4.9.2, this is an llms.txt file, used by LLMs to index the site.

# Bioaster

Microbiology Technology Institute

## Sitemaps

- [XML Sitemap](https://www.bioaster.org/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [News](https://www.bioaster.org/news/)
- [Présentation de poster en Microfluidique - MPS Worls Summit à BERLIN](https://www.bioaster.org/poster-presentation-about-microfluidics/) - 📢 Gabriele Pitingolo will participate to the #Microphysiological Systems summit- MPS World Summit 2023 from June 26th to 30th in Berlin, Germany. At this occasion, Gabriele will present his poster entitled "Process for bonding separate substrates by gelatin coating: applications in #microfluidics " on Wedenesday 2_, June during the networking break (16:30-17:50). Have a look! More info: https://lnkd.in/e8CZJSJ #bioengineering #stemcell #organonachip #imagingtechnologies #microtissue (from #Bioassays, #Microsystems & #Optical #engineering Unit)
- [Poster presentation about Microfluidics - MPS World summit in BERLIN](https://www.bioaster.org/poster-presentation-about-microfluidics/) - 📢 Gabriele Pitingolo will participate to the #Microphysiological Systems summit- MPS World Summit 2023 from June 26th to 30th in Berlin, Germany. At this occasion, Gabriele will present his poster entitled "Process for bonding separate substrates by gelatin coating: applications in #microfluidics " on Wedenesday 2_, June during the networking break (16:30-17:50). Have a look! More info: https://lnkd.in/e8CZJSJ #bioengineering #stemcell #organonachip #imagingtechnologies #microtissue (from #Bioassays, #Microsystems & #Optical #engineering Unit)
- [Ongoing clinical studies: ISOLATION OF BACTERIA OF HEALTH INTEREST FROM STOOL COLLECTED FROM CENTENARIAN PERSONS](https://www.bioaster.org/clinical-trial-opened-bacteria-isolation-from-stools-collected-from-centenarians-people-biscote/) - NAME of the study: BISCOTE (Bacteria Isolation from Stools Collected from Centenarians People) Sponsor : BIOASTER Collaborator: Gerond’if (Gérontopole d’Ile de France) Main investigator: Pr Olivier HANON Brief Summary: The compositional analysis of commensal bacterial populations collected from a variety of clinical samples has been recently made possible with the availability of Next Generation Sequencing
- [Venez rencontrer les équipes de BIOASTER en JUIN!](https://www.bioaster.org/meet-bioaster-teams-in-june/)
- [Etude clinique en cours: ISOLEMENT DE BACTÉRIES D'INTERET POUR LA SANTE A PARTIR DE SELLES COLLECTÉES AUPRÈS DE PERSONNES CENTENAIRES](https://www.bioaster.org/clinical-trial-opened-bacteria-isolation-from-stools-collected-from-centenarians-people-biscote/) - NOM de l’étude : BISCOTE (Bacteria Isolation from Stools Collected from Centenarians People) Promoteur : BIOASTER Collaborateur : Gérond’if (Gérontopole d’Ile de France) Principal investigateur: Pr Olivier HANON Bref résumé: L’analyse de la composition des populations bactériennes commensales collectées à partir d’une variété d’échantillons cliniques a été récemment rendue possible grâce à la disponibilité des
- [The End for BIOASTER, Technological Research Institute in microbiology and infectious diseases.](https://www.bioaster.org/fin-dactivite-et-dissolution-de-bioaster-institut-de-recherche-technologique-en-microbiologie-et-maladies-infectieuses/) - The Board of Directors meeting of July 7, 2025, formally approved the closure of the IRT BIOASTER and the dissolution of the Scientific Cooperation Foundation. BIOASTER's stakeholders—namely, the French Government, the industrial and academic founders—decided not to open a new round of funding, a prerequisite for the Institute's continued operation. Despite the scientific and technological
- [Fin d’activité et dissolution de BIOASTER, Institut de Recherche Technologique en microbiologie et maladies infectieuses.](https://www.bioaster.org/fin-dactivite-et-dissolution-de-bioaster-institut-de-recherche-technologique-en-microbiologie-et-maladies-infectieuses/) - Il a été acté au Conseil d’Administration du 7 juillet 2025 la fin des activités de l’IRT BIOASTER et la dissolution de la Fondation de Coopération Scientifique. Les parties prenantes de BIOASTER, i.e. l’Etat, les fondateurs industriels et académiques, ont décidé de ne pas ouvrir une nouvelle tranche de financement, condition sine qua non de
- [Read our new publication](https://www.bioaster.org/read-our-new-publication/) - Identification and antifungal susceptibility patterns of reference yeast strains to novel and conventional agents: a comparative study using CLSI, EUCAST and Sensititre YeastOne methods
- [Evolution de la gouvernance de l'Institut](https://www.bioaster.org/fr/evolution-de-la-gouvernance-de-linstitut/) - Voir tous nos derniers communiqués de presse Monsieur Alexandre Moulin, précédemment Directeur Général Adjoint de BIOASTER, est nommé Directeur Général de BIOASTER Monsieur Christophe Védrine, précédemment Directeur des Technologies de BIOASTER, est nommé Directeur Scientifique et Directeur des Technologies
- [Evolution of the governance](https://www.bioaster.org/evolution-of-the-governance/) - See all our latest press releases Mr. Alexandre Moulin, previously Deputy Managing Director of BIOASTER, is appointed Managing Director of BIOASTER. Mr. Christophe Védrine, previously Director of Technologies at BIOASTER, is appointed Scientific Director and Director of Technologies
- [Nouvelle collaboration avec FUNPEP](https://www.bioaster.org/fr/nouvelle-collaboration-avec-funpep/) - CP_BIOASTER_FUNPEP_MARCH31_2025_PressRelease OK OC 260325
- [New collaboration with FUNPEP](https://www.bioaster.org/new-collaboration-with-funpep/) - CP_BIOASTER_FUNPEP_MARCH31_2025_PressRelease OK OC 260325
- [Nouvelle publication dans Nature Communications](https://www.bioaster.org/fr/nouvelle-publication-dans-nature-communications/) - Publication alert: Our colleague Dr. Magali Sarafian has just published in Nature Communications, as co-first author. In this work, they demonstrated a robust daily rhythm in the overall circulating bile acid pool of healthy male participants. This targeted panel is now available at Bioaster and may help to better understand the pivotal role of the
- [New publication in Nature communications](https://www.bioaster.org/new-publication-in-nature-communication/) - Publication alert: Our colleague Dr. Magali Sarafian has just published in Nature Communications, as co-first author. In this work, they demonstrated a robust daily rhythm in the overall circulating bile acid pool of healthy male participants. This targeted panel is now available at Bioaster and may help to better understand the pivotal role of the
- [New collaboration  with STARFISH Bioscience](https://www.bioaster.org/new-collaboration-with-starfishbio/) - BIOASTER and STARFISH Bioscience Sign Strategic Agreement to Advance Discovery and Cultivation of Anaerobic Soil Bacteria
- [New collaboration  with STARFISH Bioscience](https://www.bioaster.org/new-collaboration-with-starfishbio/) - BIOASTER and STARFISH Bioscience Sign Strategic Agreement to Advance Discovery and Cultivation of Anaerobic Soil Bacteria
- [new publication in Critical Care](https://www.bioaster.org/new-publication-in-critical-care/) - Towards personalized medicine: a scoping review of immunotherapy in sepsis
- [new publication in Critical Care](https://www.bioaster.org/new-publication-in-critical-care/) - Towards personalized medicine: a scoping review of immunotherapy in sepsis
- [Meet us to the next events...](https://www.bioaster.org/meet-us-to-the-next-events-2/) - Meet us !
- [New sequencer @BIOASTER](https://www.bioaster.org/9996/) - BIOASTER is pleased to announce the recent acquisition of the newest GridION, a sequencer of third generation entirely developed by Oxford Nanopore Technologies. This installation is the logical consequence of a MinION and the MinION Mk1C already in function in the laboratory. This system allows a five-fold throughput increase in long-read sequencing for our genomics,
- [Meet us to the next events...](https://www.bioaster.org/meet-us-to-the-next-events/) - Meet us !
- [Nouvelle collaboration !](https://www.bioaster.org/fr/nouvelle-collaboration/) - BIOASTER collaborates with ZYNNON to advance VOC-based detection and identification of pathogens in clinical and industrial microbiology settings BIOASTER - Lyon, France, ZYNNON AG - Schindellegi, Switzerland, September 26, 2024 BIOASTER and ZYNNON are excited to announce a strategic collaboration focused on the innovative use of volatile organic compounds (VOCs) for the detection
- [New collaboration!](https://www.bioaster.org/new-collaboration/) - BIOASTER collaborates with ZYNNON to advance VOC-based detection and identification of pathogens in clinical and industrial microbiology settings BIOASTER - Lyon, France, ZYNNON AG - Schindellegi, Switzerland, September 26, 2024 BIOASTER and ZYNNON are excited to announce a strategic collaboration focused on the innovative use of volatile organic compounds (VOCs) for the detection
- [Retrouvez-nous dans les prochains évènements...](https://www.bioaster.org/fr/retrouvez-nous-dans-les-prochains-evenements/) - Retrouvez-nous à ces évènements en 2024!
- [Retrouvez-nous dans les prochains évènements...](https://www.bioaster.org/meet-us-to-the-next-events/) - Retrouvez-nous à ces évènements en 2024!
- [EVENT ADAY@BIOASTER « The race against Antimicrobial Resistance » in Lyon, June 11th, 2024](https://www.bioaster.org/event-adaybioaster-the-race-against-antimicrobials-resistance/) - You work in the field of antimicrobials and you wish to participate to the new edition of ADAY@BIOASTER about "The Race against Antimicrobial resistance"? send us a mail to: communication@bioaster.org to apply for an invitation! PROGRAM: The number of places is limited, we will confirm quickly by email the possibility of welcoming you
- [EVENEMENT ADAY@BIOASTER  « The race against Antimicrobial Resistance » in Lyon, June 11th, 2024](https://www.bioaster.org/event-adaybioaster-the-race-against-antimicrobials-resistance/) - Vous travaillez dans le domaine des antimicrobiens et vous souhaitez participer à la nouvelle édition de ADAY@BIOASTER sur le thème "The race against Antimicrobial Resistance"? Envoyez-nous votre demande d'invitation par mail à : communication@bioaster.org, nous vous répondrons rapidement sur la possibilité de vous recevoir (le nombre de places étant limité) PROGRAMME: Le nombre
- [BIOASTER, standardisation en microfluidique.](https://www.bioaster.org/fr/bioaster-standardisation-en-microfluidique/) - BIOASTER est devenu membre de la commission française AFNOR/B35A (équipement et matériel de laboratoire) et ISO TC 48 WG3 (International Organization for Standardization). Cela permet de standardiser les équipements du laboratoire (comptabilité, utilisation et étalonnage, sécurité, évaluations…) notamment dans le domaine de la microfluidique et de l’organe sur puce. Notre expertise dans le domaine de l’innovation
- [BIOASTER dans la Gazette du laboratoire!](https://www.bioaster.org/fr/bioaster-dans-la-gazette-du-laboratoire/) - Merci à la Gazette du laboratoire pour ce bel article sur notre Institut! #innovationouverte #biodistrict #microbiologie Téléchargez l'article. Retrouvez la gazette du laboratoire https://www.gazettelabo.fr/
- [ERA4TB:Progess and Achievements](https://www.bioaster.org/era4tbprogess-and-achievements/) - BIOASTER is proud to be part of ERA4TB (European Regimen Accelerator for #Tuberculosis) project, a public-private initiative devoted to accelerating the development of new treatment regimens for tuberculosis. The ERA4TB platform is based on a progression pipeline that can cater simultaneously for a variety of molecules at different stages of development. 📺 Watch the following
- [Meet us there!](https://www.bioaster.org/meet-us-there-2/)
- [Retrouvez-nous ici!](https://www.bioaster.org/meet-us-there-2/)
- [Nouveau séquenceur @BIOASTER](https://www.bioaster.org/9996/) - BIOASTER est heureux d'annoncer la récente acquisition du tout dernier GridION, un séquenceur de troisième génération entièrement développé par Oxford Nanopore Technologies. Cette installation est la conséquence logique d'un MinION et du MinION Mk1C déjà en fonction en laboratoire. Ce système permet de multiplier par cinq le débit de séquençage à lecture longue pour nos
- [ERA4TB : Progrès et réalisations](https://www.bioaster.org/era4tbprogess-and-achievements/) - BIOASTER est fier de faire partie du projet ERA4TB (European Regimen Accelerator for #Tuberculosis), une initiative public-privé consacrée à l'accélération du développement de nouveaux schémas thérapeutiques contre la tuberculose. La plateforme ERA4TB repose sur un pipeline de progression pouvant répondre simultanément à une variété de molécules à différents stades de développement. 📺 Regardez la vidéo
- [BIOASTER wishes you an HAPPY NEW YEAR 2024!](https://www.bioaster.org/bioaster-wishes-you-an-happy-new-year-2024/)
- [BIOASTER au coeur du Biodistict de Gerland !](https://www.bioaster.org/bioaster-in-the-heart-of-biodistrict-gerland/) - BIOASTER au coeur du Biodistrict de Gerland, Lyon ! Voir la vidéo: https://youtu.be/prRQ3qMjWKc
- [New publication about Deep longitudinal multi-omics analysis of Bordetella Pertussis](https://www.bioaster.org/new-publication-about-deep-longitudinal-multi-omics-analysis-of-bordetella-pertussis/) - New publication annoncement entitled "Deep longitudinal multi-omics analysis of Bordetella pertussis cultivated in bioreactors highlights medium starvations and transitory metabolisms, associated to vaccine antigen biosynthesis variations and global virulence regulation" on Frontiers in Microbiology review. DOI: https://doi.org/10.3389/fmicb.2023.1036386 Thanks to all BIOASTER teams in collaboration with SANOFI.
- [Meet us in April 2023!](https://www.bioaster.org/meet-us-in-april-2023/) - Join our team in April there!
- [BIOASTER in the heart of Biodistrict Gerland!](https://www.bioaster.org/bioaster-in-the-heart-of-biodistrict-gerland/) - BIOASTER in the heart of the Biodistrict Gerland, Lyon! Watch the video: https://youtu.be/prRQ3qMjWKc
- [New publication 'A MALDI-TOF MS library for rapid identification of human commensal gut bacteria from the class Clostridia'](https://www.bioaster.org/new-publication-a-maldi-tof-ms-library-for-rapid-identification-of-human-commensal-gut-bacteria-from-the-class-clostridia/) - Read our new publication entitled 'A MALDI-TOF MS library for rapid identification of human commensal gut bacteria from the class Clostridia' published on Frontiers in Microbiology. https://doi.org/10.3389/fmicb.2023.1104707
- [Mass spectrometer improvement: check it out!](https://www.bioaster.org/mass-spectrometer-improvement-check-it-out/) - BIOASTER is proud to share a successful installation of our new HPLC: Vanquish Neo (Thermofisher) coupled to our mass spectrometer Exploris 480 (Thermofisher). This system will allow us to increase our analytical performances with better efficiency, stability and reproducibility on sample analysis such as biofluids, feces and bacteria. Our metabolomic-proteomic lab will have access to
- [BIOASTER Awarded Grant to Develop Multiplex Rapid Diagnostics for Neglected Tropical Diseases Plaguing Millions Globally](https://www.bioaster.org/bioaster-awarded-grant-to-develop-multiplex-rapid-diagnostics-for-neglected-tropical-diseases-plaguing-millions-globally/) - Onchocerciasis, also known as river blindness, stands as the second leading cause of infectious blindness worldwide. According to estimates by the World Health Organization (WHO), approximately 25 million people are infected globally, with another 90 million at risk. Over 99% of these cases occur in Africa, and vision loss affects around 1.15 million
- [Meet us there in September! Part 1](https://www.bioaster.org/meet-us-there-in-september-part-1/) - Meet us at these events on September Part 1! #biostatistics #antimicrobials #multiomics #data #microbiome #r&dbusiness #asia #prebiotics #probiotics #anoxic #culturomics More information = @ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, Dr Derry MERCER will present a poster entitled: "HoloMoA: Digital Inline Holographic Microscopy to Rapidly and Cost-effectively Determine the
- [Join BIOASTER on october!](https://www.bioaster.org/join-bioaster-on-october/) - Busy month on October! Meet our teams there!
- [Join BIOASTER on October PART II](https://www.bioaster.org/join-bioaster-on-october-part-ii/) - PART II ! Busy month on October! Meet our teams there!
- [Meet us on Congress in November 2023!](https://www.bioaster.org/meet-us-on-congress-in-november-2023/) - Meet our teams over there!
- [Meet us there!](https://www.bioaster.org/meet-us-there/) - Meet our Diagnotics and Antimicrobials's teams at BioFIT Life sciences partnering conference from December 12th to 13th at Marseille, France.
- [New Publication about Metagenomics for the microbiological diagnosis...  on BMC- Respiratory Research](https://www.bioaster.org/new-publication-about-metagenomics-for-the-microbiological-diagnosis-on-bmc-respiratory-research/) - New publication on BMC journal>Respiratory Research! About "Metagenomics for the microbiological diagnosis of hospital-acquired pneumonia and ventilator-associated pneumonia (HAP/VAP) in intensive care unit (ICU): a proof-of-concept study" Doi Find all our scientific communications by clicking here!
- [BIOASTER vous souhaite une très belle année 2024!](https://www.bioaster.org/bioaster-wishes-you-an-happy-new-year-2024/) - BIOASTER et toutes ses équipes vous souhaitent une excellente nouvelle année 2024! 🧨🧨✨✨🎆
- [BIOASTER wishes you an HAPPY HOLIDAY SEASON!](https://www.bioaster.org/bioaster-wishes-you-an-happy-holyday-season/) - BIOASTER wishes you an HAPPY HOLIDAY SEASON! We wish you a very joyful Christmas, a pleasant and relaxing time with your loved ones.
- [Communiqué de Presse S.O.L.V.E AMR : initiative conjointe avec Cynbiose, Pharmalex et ICTA](https://www.bioaster.org/communique-de-presse-s-o-l-v-e-amr-initiative-conjointe-avec-cynbiose-pharmalex-et-icta/) - C’est avec plaisir que nous vous partageons le communiqué sur le lancement de notre initiative «S.O.L.V.E. AMR» conjointe avec Cynbiose, Pharmalex et ICTA. S.O.L.V.E AMR (Solutions for Overcoming and Leveraging Versatile Efforts Against Microbial Resistance) En synthèse, par nos expertises, plateaux techniques et compétences complémentaires, nous avons collectivement pour ambition d’accompagner les entreprises qui développent
- [Poster presentation about Multi-omics data @ ISMB/ECCB congresses, Lyon, France](https://www.bioaster.org/9506/) - 📢 BIOASTER will present a poster at the 31st conference on Intelligent Systems for Molecular Biology & 22nd European Conference on Computational Biology (July 23-27th, 2023) in Lyon, France. Alexei Novoloaca presents a poster entitled "Comparative analysis of supervised integrative methods for #multiomics #data " in collaboration with Bill & Melinda Gates Medical Research Institute 📌 Meet him on Tuesday, July 25th
- [New publication about DNA extraction methods for 16S rRNA gene sequencing - In collaboration with BioMerieux](https://www.bioaster.org/new-publication-about-dna-extraction-methods-for-16s-rrna-gene-sequencing-with-biomerieux/) - BIOASTER is pleased to share its comparison results of DNA extraction methods for 16S rRNA gene sequencing in the analysis of the human gut microbiome in collaboration with BioMérieux (https://doi.org/10.1038/s41598-023-33959-6). BIOASTER is continuously working on identifying new methods to process your samples to offer high quality metagenomics data for your research. Through this work, we
- [Press Release S.O.L.V.E AMR : joint initiative with Cynbiose, Pharmalex & ICTA](https://www.bioaster.org/communique-de-presse-s-o-l-v-e-amr-initiative-conjointe-avec-cynbiose-pharmalex-et-icta/) - We are pleased to share with you the press release on our joint "S.O.L.V.E. AMR" initiative with Cynbiose, Pharmalex and ICTA. S.O.L.V.E AMR (Solutions for Overcoming and Leveraging Versatile Efforts Against Microbial Resistance) Briefly, through our expertise, technical platforms and complementary skills, our collective ambition is to support companies that are developing innovative solutions to
- [New publication "Cysteamine-mediated blockade of the glycine cleavage system modulates epithelial cell inflammatory and innate immune responses to viral infection".](https://www.bioaster.org/new-publication-cysteamine-mediated-blockade-of-the-glycine-cleavage-system-modulates-epithelial-cell-inflammatory-and-innate-immune-responses-to-viral-infection/) - New publication from Dr. Derry Mercer, Antimicrobials Program Head in Elsevier>Biochemical and Biophysical Research Communications journal. Entitled: "Cysteamine-mediated blockade of the glycine cleavage system modulates epithelial cell inflammatory and innate immune responses to viral infection". Link to the article: https://doi.org/10.1016/j.bbrc.2023.08.021
- [INCATE and BIOASTER join forces to improve support to AMR innovators](https://www.bioaster.org/incate-and-bioaster-join-forces-to-improve-support-to-amr-innovators/) - INCATE (the INCubator for Antibacterial Therapies in Europe) and BIOASTER, the French Microbiology Technology Research Institute, have announced this week the beginning of a new partnership that aims to improve the support to innovators to fight drug-resistant infections. Antimicrobial resistance (AMR) is the ability of pathogens to prevent antibiotics from working against them and it
- [Outsmarting technological challenges](https://www.bioaster.org/outsmarting-technological-challenges/) - Welcome to BIOASTER! Want to know more about our technological added values : check our OFFERS page What can you expect from BIOASTER?: Visit A project with BIOASTER page to learn more.
- [Nouvelle publication sur Metagenomics for the microbiological diagnosis...  dans le journal BMC- Respiratory Research](https://www.bioaster.org/new-publication-about-metagenomics-for-the-microbiological-diagnosis-on-bmc-respiratory-research/) - Nouvelle publication dans le journal BMC >Respiratory Research! Titrée "Metagenomics for the microbiological diagnosis of hospital-acquired pneumonia and ventilator-associated pneumonia (HAP/VAP) in intensive care unit (ICU): a proof-of-concept study" Doi Retourvez toutes nos communications scientifiques en cliquant ici!
- [Certified Laboratory of biocrates for BIOASTER](https://www.bioaster.org/bioaster-is-a-certified-lab-on-biocrates/) - Our OMIC team successfully completed Biocrates training and is now part of the certified laboratories able to handle this technology (Certified laboratories - biocrates life sciences ag). High quality metabolomic data is obtained by quantification of hundreds of metabolites and lipids. This certification allows Bioaster to boost our expertise in the analysis of metabolite of interest and
- [BIOASTER fait parti des laboratoires certifiés- Biocrates](https://www.bioaster.org/bioaster-is-a-certified-lab-on-biocrates/) - Notre équipe OMIC a suivi avec succès la formation Biocrates et fait désormais partie des laboratoires certifiés capables de maîtriser cette technologie (Laboratoires certifiés - biocrates life sciences ag). Des données métabolomiques de haute qualité sont obtenues par quantification de centaines de métabolites et de lipides. Cette certification permet à BIOASTER de renforcer son expertise
- [Nouvelle publication scientifique: "Cysteamine-mediated blockade of the glycine cleavage system modulates epithelial cell inflammatory and innate immune responses to viral infection".](https://www.bioaster.org/new-publication-cysteamine-mediated-blockade-of-the-glycine-cleavage-system-modulates-epithelial-cell-inflammatory-and-innate-immune-responses-to-viral-infection/) - Nouvelle publication du Dr. Derry Mercer, Responsable du programme Antimicrobiens de BIOASTER dans la revue: Elsevier>Biochemical and Biophysical Research Communications journal. Entitled: "Cysteamine-mediated blockade of the glycine cleavage system modulates epithelial cell inflammatory and innate immune responses to viral infection". Link to the article: https://doi.org/10.1016/j.bbrc.2023.08.021
- [Rencontrez nous ici!](https://www.bioaster.org/meet-us-there/) - Rencontrez nos équipes Diagnostic et Antimicrobiens à la conférence BioFIT Life sciences Partnering du 12 au 13 décembre à Marseille, France.
- [BIOASTER collabore avec QIAGEN sur sur le développement de tests multiplex pour maladies infectieuses](https://www.bioaster.org/bioaster-announced-a-collaboration-with-qiagen-on-infectious-disease-multiplex-assay-development/) - BIOASTER annonce aujourd'hui une collaboration avec QIAGEN pour le développement d'un test de diagnostic moléculaire fonctionnant sur la plateforme QIAstat-Dx de QIAGEN. L’objectif principal de la collaboration est d’élargir et d’accélérer le développement du panel d’applications cliniques avec la solution de tests syndromiques de QIAGEN dans le domaine des maladies infectieuses. Télécharger le Communiqué
- [BIOASTER announced a collaboration with QIAGEN on infectious disease multiplex assay development](https://www.bioaster.org/bioaster-announced-a-collaboration-with-qiagen-on-infectious-disease-multiplex-assay-development/) - BIOASTER, today announced a collaboration with QIAGEN for the development of a molecular diagnostic assay running on the QIAGEN’s QIAstat-Dx platform. The primary objective of the collaboration is to expand and speed up the development of the panel of clinical applications with QIAGEN’s syndromic testing solution in the field of infectious diseases. Upload the complete
- [INCATE et BIOASTER unissent leurs forces pour améliorer le soutien aux innovateurs en matière de Résistance aux Antimicrobiens](https://www.bioaster.org/incate-and-bioaster-join-forces-to-improve-support-to-amr-innovators/) - INCATE (l'incubateur pour les thérapies antibactériennes en Europe) et BIOASTER, (l'Institut français de recherche technologique en microbiologie), ont annoncé cette semaine le début d'un nouveau partenariat visant à améliorer le soutien aux innovateurs pour lutter contre les infections pharmaco résistantes. La résistance aux antimicrobiens (RAM) est la capacité des agents pathogènes à empêcher les antibiotiques
- [Retrouvez nous dans ces congrès en Novembre 2023!](https://www.bioaster.org/meet-us-on-congress-in-november-2023/) - Retrouvez nous ici!
- [Retrouvez les équipes BIOASTER en Octobre PARTIE II!](https://www.bioaster.org/join-bioaster-on-october-part-ii/) - PARTIE II !Beaucoup de congrès en ce mois d'octobre! Venez rencontrer nos équipes ici!
- [Rencontrez BIOASTER en Octobre!](https://www.bioaster.org/join-bioaster-on-october/) - Ce mois d'octobre est chargé! Rencontrez nos équipes ici!
- [Nouveau dans notre labo OMICS: robot Firefly®!](https://www.bioaster.org/new-in-our-lab-firefly-robot/) - BIOASTER est fier d'annoncer l'installation du premier robot firefly® installé en France (par SPT Labtech) au sein de l'Unité OMICS ! Ce robot simplifiera et standardisera nos différents flux de travail transcriptomique et génomique. Cela profitera à tous nos partenaires : davantage d’échantillons seront traités de manière standardisée et dans des délais réduits. Merci à
- [New in our lab: Firefly® robot!](https://www.bioaster.org/new-in-our-lab-firefly-robot/) - BIOASTER is proud to announce the setup of -the first installed in France- firefly® robot (SPT Labtech) within the OMICS Unit! This robot will simplify and standardize our different transcriptomics and genomics workflows. This will benefit to all our partners: more samples will be processed in a standardized way and shortened time. Thanks to SPT
- [Meeting at Microbiome R&D and Business Congress: ASIA](https://www.bioaster.org/meeting-at-microbiome-rd-and-business-congress-asia/) - Meet our Microbiome program team (Dr. Thomas LEICHT & Dr. Ilia BELOTSERKOVSKY ) at the next Microbiome R&D and Business Congress: ASIA in Seoul , South Korea on Septembre 12th, 13th. September 12th 2:25pm: Dr. Ilia BELOTSERKOVSKY's TALK entitled "Ex-vivo experimental approaches to explore immunomodulatory and homeostatic potential of pre- and probiotics" Then meet the
- [Meeting at Microbiome R&D and Business Congress: ASIA](https://www.bioaster.org/meeting-at-microbiome-rd-and-business-congress-asia/) - Meet our Microbiome program team (Dr. Thomas LEICHT & Dr. Ilia BELOTSERKOVSKY ) at the next Microbiome R&D and Business Congress: ASIA in Seoul , South Korea on Septembre 12th, 13th. September 12th 2:25pm: Dr. Ilia BELOTSERKOVSKY's TALK entitled "Ex-vivo experimental approaches to explore immunomodulatory and homeostatic potential of pre- and probiotics" Then meet the
- [New Publication about gut microbiota & diabetes patients - in collaboration with Genetic Analysis](https://www.bioaster.org/new-publication-about-gut-microbiota-diabetes-patients-in-collaboration-with-genetic-analysis/) - BIOASTER is glad to share the last scientific article published in BMC Endocrine Disorders in August 2023 in collaboration with the team of Genetic Analysis (www.genetic-analysis.com). The aim of this study was to explore the gut microbiota and bacteria associated with prediabetes patients, and treatment naive type 2 diabetes patients, compared to healthy subjects. A
- [Nouvelle publication sur le microbiote intestinal et les patients diabétiques - en collaboration avec Genetic Analysis](https://www.bioaster.org/new-publication-about-gut-microbiota-diabetes-patients-in-collaboration-with-genetic-analysis/) - BIOASTER est heureux de partager le dernier article scientifique publié dans BMC Endocrine Disorders en août 2023 en collaboration avec l'équipe de Genetic Analysis (www.genetic-analysis.com). Le but de cette étude était d’explorer le microbiote intestinal et les bactéries associées aux patients prédiabétiques et aux patients diabétiques de type 2 non traités, par rapport aux sujets
- [New publication about Antimicrobial resistance](https://www.bioaster.org/new-publication-about-antimicrobial-resistance/) - Read our new publication entitled "Antimicrobial Resistance: a Biochemical Society position statement" available on The biochemist review with Dr. Derry Mercer, BIOASTER head of Antimicrobial programme. https://doi.org/10.1042/bio_2022_148
- [Nouvelle publication sur les méthodes d'extraction d'ADN pour le séquençage des gènes d'ARNr 16S - en collaboration avec BioMérieux](https://www.bioaster.org/new-publication-about-dna-extraction-methods-for-16s-rrna-gene-sequencing-with-biomerieux/) - BIOASTER est fier de partager ses résultats de comparaison de méthodes d’extraction d’ADN pour le séquençage du gène ARNr 16S pour l’analyse du microbiote intestinal humain en collaboration avec BioMérieux (https://doi.org/10.1038/s41598-023-33959-6). BIOASTER continue de travailler à l’identification de nouvelles méthodes pour traiter vos échantillons et offrir des données de métagenomique de qualités pour vos projets
- [Retrouvez nous à ces évènements! Partie 1](https://www.bioaster.org/meet-us-there-in-september-part-1/) - Retrouvez nous à ces évènements! Partie 1 #biostatistics #antimicrobials #multiomics #data #microbiome #r&dbusiness #asia #prebiotics #probiotics #anoxic #culturomics More information = @ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, Dr Derry MERCER will present a poster entitled: "HoloMoA: Digital Inline Holographic Microscopy to Rapidly and Cost-effectively Determine the Mechanism of
- [Présentation Poster sur les données multi-omiques aux congrès ISMB/ECCB, Lyon, France](https://www.bioaster.org/9506/) - 📢 BIOASTER présentera un poster à la 31e conférence sur les Systèmes Intelligents pour la Biologie Moléculaire et à la 22e conférence Européenne sur la Biologie Computationnelle (23-27 juillet 2023) à Lyon, France. Alexei Novoloaca présente un poster intitulé "Comparative analysis of supervised integrative methods for #multiomics #data " en collaboration avec Bill & Melinda
- [Meet BIOASTER teams in June!](https://www.bioaster.org/meet-bioaster-teams-in-june/) - Meet BIOASTER teams there in June! A very busy month!
- [BIOASTER reçoit une subvention pour développer des diagnostics rapides multiplex pour les maladies tropicales négligées qui affligent des millions de personnes dans le monde](https://www.bioaster.org/bioaster-awarded-grant-to-develop-multiplex-rapid-diagnostics-for-neglected-tropical-diseases-plaguing-millions-globally/) - L'onchocercose, également connue sous le nom de cécité des rivières, est la deuxième cause de cécité infectieuse dans le monde. Selon les estimations de l'Organisation mondiale de la santé (OMS), environ 25 millions de personnes sont infectées dans le monde, et 90 millions supplémentaires sont à risque. Plus de 99 % de ces cas
- [Reportage BIOASTER - Magazine de la santé France 5](https://www.bioaster.org/fr/reportage-bioaster-magazine-de-la-sante-france-5/) - Extrait du magazine de la Santé sur France 5 diffusé le 22 juin 2023. Reportage dans les locaux de BIOASTER à Paris. https://www.bioaster.org/composants/uploads/2023/06/Le-Magazine-De-La-Sante-France-52023-06-22-15H43m32s.mp4
- [ImmunoSEP: New animated video released about EU research project](https://www.bioaster.org/immunosep-new-animated-video-released-about-eu-research-project/) - News Release ImmunoSep: EU research project releases new animated video on personalised immunotherapy in sepsis. ImmunoSep challenges the standard ‘one-size-fits-all’ treatment approach to sepsis, which currently consists of the prescription of antibiotics and the introduction of intensive care units, by developing innovative options for future personalised immunotherapy. The brand-new animated video, just released by the
- [FunHoMic Conference - April 5-6, 2023, Dubrovnik, Croatia](https://www.bioaster.org/funhomic-conference-april-5-6-2023-dubrovnik-croatia/) - As a member of the FunHoMic Network, BIOASTER invites you to join to the final FunHoMic's conference on April 5 and 6, 2023 about “The Fungus-Host-Microbiota interplay” that will take place in the Sheraton Riviera Hotel Dubrovnik, Croatia. The international conference will cover novel aspects on fungal pathogenesis, immunology, microbial ecology, and ‘omics' technologies. An
- [Meet BIOASTER in March!](https://www.bioaster.org/meet-bioaster-in-march/) - Meet BIOASTER team in March at these events!
- [BIOASTER, member of VALUE-DX's consortium publishes a paper on BJGP Open review.](https://www.bioaster.org/bioaster-member-of-value-dxs-consortium-publishes-a-paper-on-bjgp-open-review/) - BIOASTER, proud member of the VALUE-Dx's consortium! 📢 Paper on BJGP Open about the difference in testing & prescribing for #respiratory tract #infection across 18 European countries is number 1 🥇Most read Research Article for 2022! DOI: https://doi.org/10.3399/BJGPO.2021.0212 👏 👏 Congratulations to the authors and the PC Research Network! #antibiotics #antimicrobialstewardship #antibioticstewardship #amr
- [New publication : Prior SARS-CoV-2 infection enhances and reshapes spike protein-specific memory induced by vaccination](https://www.bioaster.org/new-publication-prior-sars-cov-2-infection-enhances-and-reshapes-spike-protein-specific-memory-induced-by-vaccination/) - Have a look to the new publication of BIOASTER team (authors: Natacha Mariano & Julie Chaix) entitled: "Prior SARS-CoV-2 infection enhances and reshapes spike protein-specific memory induced by vaccination" on Science Translational Medicine review. DOI: https://www.science.org/doi/10.1126/scitranslmed.ade0550
- [Join BIOASTER teams in MAY!](https://www.bioaster.org/join-bioaster-teams-on-may/) - You can meet BIOASTER team there in MAY!
- [Retrouvez BIOASTER en Mars!](https://www.bioaster.org/meet-bioaster-in-march/) - Retrouvez les équipes BIOASTER sur ces évènements en mars!
- [BIOASTER, membre du consortium VALUE-DX publie un article dans la revue BJGP Open](https://www.bioaster.org/bioaster-member-of-value-dxs-consortium-publishes-a-paper-on-bjgp-open-review/) - BIOASTER, fier membre du consortium VALUE-Dx ! L'article sur BJGP Open sur la différence dans les tests et la prescription des infections des voies respiratoires dans 18 pays européens est le numéro 1 🥇de l'article de recherche le plus lu en 2022 ! DOI : https://doi.org/10.3399/BJGPO.2021.0212 👏👏 Félicitations aux auteurs et au PC Research Network!
- [1ères rencontres FRANCEbiotech & ANRS\MIE: les entrerprises Healthtech & la stratégie nationale d'accélération MIE](https://www.bioaster.org/1eres-rencontres-francebiotech-anrsmie-les-entrerprises-healthtech-la-strategie-nationale-dacceleration-mie/) - BIOASTER est fier d'être partenaire pour les 1ères rencontres FRANCEbiotech & ANRS\MIE: ANRS |MIE et France Biotech organisent les 1ères rencontres entre les acteurs de la #healthtech et les #chercheurs du réseau ANRS | MIE sur la thématique des maladies infectieuses émergentes le mardi 28 mars à 14h en présentiel à PariSanté Campus. Evènement gratuit et ouvert à toutes les entreprises Healthtech
- [Nouvelle publication : "Prior SARS-CoV-2 infection enhances and reshapes spike protein-specific memory induced by vaccination"](https://www.bioaster.org/new-publication-prior-sars-cov-2-infection-enhances-and-reshapes-spike-protein-specific-memory-induced-by-vaccination/) - Découvrez la nouvelle publication de l'équipe BIOASTER (auteurs : Natacha Mariano & Julie Chaix) intitulée : "Prior SARS-CoV-2 infection enhances and reshapes spike protein-specific memory induced by vaccination" sur la revue Science Translational Medicine. DOI : https://www.science.org/doi/10.1126/scitranslmed.ade0550
- [Conférence FunHoMic - 5 et 6 avril 2023 , Dubrovnik, Croatie](https://www.bioaster.org/funhomic-conference-april-5-6-2023-dubrovnik-croatia/) - En tant que membre du réseau FunHoMic, BIOASTER vous invite à vous joindre à la conférence finale de FunHoMic les 5 et 6 avril 2023 sur "L'interaction champignon-hôte-microbiote" qui aura lieu au Sheraton Riviera Hotel Dubrovnik, Croatie. La conférence internationale couvrira de nouveaux aspects de la pathogenèse fongique, de l'immunologie, de l'écologie microbienne et des
- [New publication about Antimicrobial resistance](https://www.bioaster.org/new-publication-about-antimicrobial-resistance/) - Retrouvez notre nouvelle publication "Antimicrobial Resistance: a Biochemical Society position statement" disponible dans la revue The biochemist avec en co-auteur Dr. Derry Mercer, Responsable du programme Antimicrobien de BIOASTER. Bonne lecture! https://doi.org/10.1042/bio_2022_148
- [Rencontrer les équipes BIOASTER en Mai!](https://www.bioaster.org/join-bioaster-teams-on-may/) - Venez rencontrer les équipes BIOASTER en MAI!
- [ImmunoSEP: Nouvelle vidéo animée diffusée sur le projet de recherche Européen](https://www.bioaster.org/immunosep-new-animated-video-released-about-eu-research-project/) - ImmunoSep : un projet de recherche de l'UE publie une nouvelle vidéo animée sur l'immunothérapie personnalisée dans le sepsis. ImmunoSep remet en question l'approche de traitement standard « taille unique » du sepsis, qui consiste actuellement en la prescription d'antibiotiques et l'introduction d'unités de soins intensifs, en développant des options innovantes pour une future immunothérapie
- [Relever les défis technologiques](https://www.bioaster.org/outsmarting-technological-challenges/) - Bienvenue chez BIOASTER ! Envie d'en savoir plus sur nos valeurs ajoutées technologiques : consultez notre page OFFRESQue pouvez-vous attendre de BIOASTER ? : Visitez la page Un projet avec BIOASTER pour en savoir plus.
- [Clinical trial opened: BACTERIA ISOLATION FROM STOOLS COLLECTED FROM CENTENARIANS PEOPLE (BISCOTE)](https://www.bioaster.org/fr/clinical-trial-opened-bacteria-isolation-from-stools-collected-from-centenarians-people-biscote/) - Sponsor : BIOASTER Collaborator: Gerond'IF (Gérontopole d'Ile de France) Study Description Brief Summary: The compositional analysis of commensal bacterial populations collected from a variety of clinical samples has been recently made possible with the availability of Next Generation Sequencing (NGS) technologies. The term 'next-generation probiotics' (NGP) is now widely used to describe these commensal species
- [Amélioration de notre spectromètre de masse: venez voir!](https://www.bioaster.org/mass-spectrometer-improvement-check-it-out/) - BIOASTER est fier de partager une installation réussie de notre nouvelle HPLC : Vanquish Neo (Thermofisher) couplée à notre spectromètre de masse Exploris 480 (Thermofisher). Ce système nous permettra d'augmenter nos performances analytiques avec une meilleure efficacité, stabilité et reproductibilité sur l'analyse d'échantillons tels que les biofluides, les matières fécales et les bactéries. Notre laboratoire
- [ADAY@BIOASTER « The future of vaccines » in Lyon, June 2nd, 2023](https://www.bioaster.org/adaybioaster-the-future-of-vaccines-in-lyon-june-2nd-2023/) - You work in the field of vaccines and you wish to participate to the new edition of Aday@BIOASTER about “The future of vaccines”. If you are interested to register, fill in the form here bellow the agenda. Please complete the form below to request an invitation Notice: JavaScript is required for this content.
- [Nouvelle publication 'A MALDI-TOF MS library for rapid identification of human commensal gut bacteria from the class Clostridia'](https://www.bioaster.org/new-publication-a-maldi-tof-ms-library-for-rapid-identification-of-human-commensal-gut-bacteria-from-the-class-clostridia/) - Retrouvez une nouvelle publication intitulée 'A MALDI-TOF MS library for rapid identification of human commensal gut bacteria from the class Clostridia' publiée dans la revue Frontiers in Microbiology. https://doi.org/10.3389/fmicb.2023.1104707
- [Rejoignez-nous en Avril 2023!](https://www.bioaster.org/meet-us-in-april-2023/) - Rejoignez nos équipes en Avril!
- [1ères rencontres FRANCEbiotech & ANRS\MIE: les entrerprises Healthtech & la stratégie nationale d'accélération MIE](https://www.bioaster.org/1eres-rencontres-francebiotech-anrsmie-les-entrerprises-healthtech-la-strategie-nationale-dacceleration-mie/) - BIOASTER est fier d'être partenaire pour les 1ères rencontres FRANCEbiotech & ANRS\MIE: ANRS |MIE et France Biotech organisent les 1ères rencontres entre les acteurs de la #healthtech et les #chercheurs du réseau ANRS | MIE sur la thématique des maladies infectieuses émergentes le mardi 28 mars à 14h en présentiel à PariSanté Campus. Evènement gratuit et ouvert à toutes les entreprises Healthtech
- [All BIOASTER's team wishes you a happy and successful NEW YEAR 2023!](https://www.bioaster.org/all-bioasters-team-wishes-you-a-happy-and-successful-new-year-2023/) - Click on the following picture to see the video: In 2022, BIOASTER celebrated its first 10 years. Thanks to our founders, partners and staff! We hope that the next 10 years will foster 10 times as many collaborations & innovation in the service of human & animal health. Let's start with 2023, we wish you
- [Toute l'équipe de BIOASTER vous souhaite une bonne et heureuse ANNEE 2023 !](https://www.bioaster.org/all-bioasters-team-wishes-you-a-happy-and-successful-new-year-2023/) - Cliquez sur le photo ci - dessous pour lancer la vidéo: En 2022, BIOASTER a fêté ses 10 premières années. Merci à nos fondateurs, partenaires et collaborateurs ! Nous espérons que les 10 prochaines années favoriseront 10 fois plus de collaborations et d'innovations au service de la santé humaine et animale. Commençons par 2023, nous
- [Open call TRANSVAC 2 TRAINING](https://www.bioaster.org/open-call-transvac-2-training/) - Keen on furthering your skills in vaccine development? 📢Open call for #TRANSVAC2 #training! FREE training from experts in the field! 💥 Three courses are open for applications: ✔M3 #Adjuvants and vaccine formulation ✔M13 #SystemsBiology in vaccinology ✔M14 #Regulatory aspects of vaccine development ✍ Apply by Dec 31 December! Don’t miss it! ➡https://www.transvac.org/transvac2 @Vaccine Formulation
- [BIOASTER is pleased to announce that the B2B2B AMR Dx consortium has officially been recommended for funding](https://www.bioaster.org/bioaster-is-pleased-to-announce-that-the-b2b2b-amr-dx-consortium-has-officially-been-recommended-for-funding/) - BIOASTER is pleased to announce that the B2B2B AMR Dx consortium has officially been recommended for funding (B2B2B AMR Dx: Bench, Bedside, Business, and Beyond: innovative solutions for AMR diagnostics) The aim of this JPIAMR transnational network call (JPIAMR 15th call; Diagnostics and Surveillance Networks) is to assemble networks of leading experts and stakeholders with
- [Meet our team to the next conferences in November](https://www.bioaster.org/meet-our-team-to-the-next-conferences-in-november/) - Meet our team there on November!
- [Press release BIOASTER and ADOR Diagnostics Collaborate in the Field of Molecular Diagnostics in Infectious Diseases](https://www.bioaster.org/press-release-bioaster-and-ador-diagnostics-collaborate-in-the-field-of-molecular-diagnostics-in-infectious-diseases/) - ADOR Diagnostics, the international IVD company headquartered in Rome and BIOASTER, the French Microbiology Technology Research Institute, have today announced the beginning of a cooperation to develop molecular diagnostic tests in the field of Sexually Transmitted Infections (STIs). Download and read the complete Press release here.
- [BIOASTER is a proud « Supporting Partner » of “Le Forum Santé Innovation” November 8, 2022 in Lyon](https://www.bioaster.org/bioaster-is-a-proud-supporting-partner-of-le-forum-sante-innovation-november-8-2022-in-lyon/) - BIOASTER is a proud « Supporting Partner » of “Le Forum Santé Innovation” on November 8, 2022 in Lyon. Program & registration : https://forum-sante-innovation.fr/
- [Meet BIOASTER on October!](https://www.bioaster.org/meet-bioaster-on-october/) - Meet BIOASTER team on october @ these events:
- [PiLeJe Laboratoire and BIOASTER collaboration to investigate health potential of a probiotic selection in the context of SARS-CoV2 infection](https://www.bioaster.org/pileje-laboratoire-and-bioaster-collaboration-to-investigate-health-potential-of-a-probiotic-selection-in-the-context-of-sars-cov2-infection/) - PiLeJe Laboratoire and BIOASTER are glad to announce the successful completion of a collaborative project that provided new insights on the immunomodulatory potential of selected probiotics in the context of Covid-19. A specifically designed in-vitro approach using human cells allowed us to evaluate the effect of PiLeJe’s product across the intestinal epithelial barrier on immune
- [BIOASTER exclusively licenses blood-based biomarkers for defining immune status of critically ill patients in intensive care units.](https://www.bioaster.org/bioaster-exclusively-licenses-blood-based-biomarkers-for-defining-immune-status-of-critically-ill-patients-in-intensive-care-units/) - Read all about the press release: HERE.
- [BLOOD-ON-CHIP INITIATIVE](https://www.bioaster.org/blood-on-chip-initiative/) - BIOASTER and Institut Pasteur are proud to join forces to build a novel microphysiological system (MPS) mimicking the first steps of immune activation during vaccination. This system will enable studying vaccine mode of action by triggering the immune cell activation in a dynamic model using circulating immune cells. Such a system takes advantage of a
- [Phage therapy at BIOASTER](https://www.bioaster.org/phage-therapy-at-bioaster/) - #PhageTherapy at BIOASTER At @Bioaster, we have developed #preclinicalModels allowing To follow the concentration of #phages over time (#pharmacokinetics) in different fluids and organs after administration by various routes On uninfected immunocompetent mice On infected immunocompetent mice To measure the effectiveness of #phageTherapy, alone (1 strain or in a cocktail), in combo with an antibiotic,
- [NOSOPHARM AND GNA NOW ANNOUNCE POSITIVE RESULTS FOR THE LATE PRECLINICAL DEVELOPMENT OF THE FIRST-IN-CLASS ANTIBIOTIC NOSO-502](https://www.bioaster.org/nosopharm-and-gna-now-announce-positive-results-for-the-late-preclinical-development-of-the-first-in-class-antibiotic-noso-502/) - An important milestone has been reached for the GNA NOW Consortium, which BIOASTER is proud to be a partner of. A Go-decision has been received for the project’s NOSO-502 program to continue preparations for the first-in-human Phase 1 clinical study! This decision demonstrates the quality and innovativeness of NOSO-502, which has the potential to treat
- [JOIN US on January 2022](https://www.bioaster.org/join-us-on-january-2022/) - Meet BIOASTER teams online!
- [New publication about COVID-19 vaccine on eBioMedicine](https://www.bioaster.org/new-publication-about-covid-19-vaccine-on-ebiomedicine/) - The COVID19-101 project in partnership with the Institut Pasteur aimed to characterize the immune response induced by the SARS-CoV-2 vaccine candidate as part of a phase I clinical study. This work resulted in a publication in eBioMedicine. https://doi.org/10.1016/j.ebiom.2021.103810
- [New Publication on "Evolution of FMT - From early clinical to standardized treatments"](https://www.bioaster.org/new-publication-on-evolution-of-fmt-from-early-clinical-to-standardized-treatments/) - New publication last week on Elsevier about: "Evolution of FMT - From early clinical to standardized treatments" Authors: Stephanie L Servetas 1, Phillip J Daschner 2, Cyril Guyard 3, Vincent Thomas 4, Herve Affagard 5, Chrysi Sergaki 6, Harry Sokol 7, Jennifer A Wargo 8, Gary D Wu 9, Philippe Sabot 10 DOI: 10.1016/j.biologicals.2022.01.004 Affiliations 1Complex Microbial Systems Group, Biosystems and Biomaterials Divison, National Institute of Standards and Technology, Gaithersburg, MD, USA. Electronic address: stephanie.servetas@nist.gov.
- [BIOASTER wishes you a healthy & prosperous new year!](https://www.bioaster.org/bioaster-wishes-you-a-healthy-prosperous-new-year/) - BIOASTER wishes you a healthy & prosperous new year! "When the going gets tough, the tough get going" Thanks to our partners, founding members and teams for keeping on building innovative solutions together for the benefit of patients. Let's go through 2022 together!
- [New Publication about Monocyte Trajectories Endotypes in Frontiers in Immunology](https://www.bioaster.org/new-publication-about-monocyte-trajectories-endotypes-in-frontiers-in-immunology/) - New publication available about "Monocyte Trajectories Endotypes Are Associated With Worsening in Septic Patients" in Frontiers in Immunology. Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection. The immune system plays a key role in sepsis onset and remains dysregulated over time in a heterogeneous manner. Here, we decipher the
- [BIOASTER is glad to be part of Cynbiome](https://www.bioaster.org/bioaster-is-glad-to-be-part-of-cynbiome/) - BIOASTER is glad to be part of Cynbiome, the 1st preclinical excellence research network dedicated to the #microbiome research applied to infectiousdiseases. Together with our partners, we will capitalize on the richness and complementarity of the best players specializing in various fields such as high-throughput sequencing, imaging, microfluidics, biomarkers, biomanufacturing, preclinical models and further link
- [New publication from BIOASTER on Gnotobiology in collaboration with the academic teams of François LEULIER and Martin SCHWARZER!](https://www.bioaster.org/new-publication-from-bioaster-on-gnotobiology-in-collaboration-with-the-academic-teams-of-francois-leulier-and-martin-schwarzer/) - New publication from BIOASTER on #Gnotobiology in collaboration with the academic teams of @François Leulier and @Martin Schwarzer! "A standardized gnotobiotic mouse model harboring a minimal 15-member mouse gut microbiota recapitulates SOPF/SPF phenotypes" published in Nature Communications. More information: https://doi.org/10.1038/s41467-021-26963-9 Or: https://www.nature.com/articles/s41467-021-26963-9
- [New Publication from REALISM Project in Frontier Immunol.](https://www.bioaster.org/new-publication-from-realism-project-in-frontier-immunol/) - New publication from REALISM collaborative project in Frontiers in Immunology about Herpes DNAemia & TTV Viraemia in Intenisve Care unit entilted: "Herpes DNAemia and TTV Viraemia in Intensive Care Unit Critically III patients: A single-Centre Propsective Longitudinal study" DOI https://doi.org/10.3389/fimmu.2021.698808
- [Meet BIOASTER teams in November!](https://www.bioaster.org/meet-bioaster-teams-in-november/) - They will be there in November! Microbiota, Metabolomics, Biofilm, Microfluidics and Phage Therapy on the menu!
- [New APPLICATION NOTE available on Proteomics with COVARIS](https://www.bioaster.org/new-application-note-available-on-proteomics-with-covaris/) - New Application note available in collaboration with COVARIS entitled: A Robust and Standardized Workflow to Analyze C. albicans differential Protein Expression using Tandem Mass Tag (TMT) Abstract Yeast samples are difficult to process for protein extraction. They are resistant to chemical lysis and exhibit phenotypic appearances which make them even harder to lyse, especially when
- [New Publication : "Blood transcriptomics reveal the evolution and resolution of the immune response in tuberculosis"](https://www.bioaster.org/new-publication-blood-transcriptomics-reveal-the-evolution-and-resolution-of-the-immune-response-in-tuberculosis/) - New publication of BIOASTER about Tuberculosis: "Blood transcriptomics reveal the evolution and resolution of the immune response in tuberculosis" in Journal of Experimental Medecine. Doi:https://doi.org/10.1084/jem.20210915 A multi partnership collaboration project about tuberculosis.
- [Meet BIOASTER team! Next congresses!](https://www.bioaster.org/meet-bioaster-team-next-congresses/) - Next congresses where you can meet BIOASTER team!!
- [Etiam porta sem malesuada magna mollis euismod. Vivamus sagittis](https://www.bioaster.org/etiam-porta-sem-malesuada-magna-mollis-euismod-vivamus-sagittis/)
- [Cras justo odio, dapibus ac facilisis in, egestas eget quam. Morbi leo risus, porta ac consectetur ac, vestibulum](https://www.bioaster.org/cras-justo-odio-dapibus-ac-facilisis-in-egestas-eget-quam-morbi-leo-risus-porta-ac-consectetur-ac-vestibulum/)
- [Vestibulum at eros. Aenean lacinia bibendum nulla.](https://www.bioaster.org/vestibulum-at-eros-aenean-lacinia-bibendum-nulla/)
- [Vestibulum at eros. Aenean lacinia bibendum nulla.](https://www.bioaster.org/vestibulum-at-eros-aenean-lacinia-bibendum-nulla/)
- [Cras justo odio, dapibus ac facilisis in, egestas eget quam. Morbi leo risus, porta ac consectetur ac, vestibulum](https://www.bioaster.org/cras-justo-odio-dapibus-ac-facilisis-in-egestas-eget-quam-morbi-leo-risus-porta-ac-consectetur-ac-vestibulum/)
- [Etiam porta sem malesuada magna mollis euismod. Vivamus sagittis](https://www.bioaster.org/etiam-porta-sem-malesuada-magna-mollis-euismod-vivamus-sagittis/)
- [LUMI-Seq®: Nouvelle vidéo en ligne!](https://www.bioaster.org/lumi-seq-nouvelle-video-en-ligne/) - LUMI-Seq®: Nouvelle vidéo en ligne Découvrez la nouvelle vidéo technologie Designed BY BIOASTER sur la technologie LUMI-Seq® : Une nouvelle approche de séquençage ciblé permettant la génération de longues séquences à partir des séquenceurs Illumina.
- [LUMI-Seq®: New video on line!](https://www.bioaster.org/lumi-seq-nouvelle-video-en-ligne/) - LUMI-Seq®: New video on line! Check out the new Designed BY BIOASTER video about LUMI-Seq® technology: A novel targeted sequencing technology for generating long reads from Illumina sequencers.
- [New publication - Science Translational Medicine](https://www.bioaster.org/new-publication-science-translational-medicine/) - “The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to Plasmodium falciparum parasite resistance” Dr Gilles Courtemanche, BIOASTER Antimicrobials Program Head is co-author of a scientific publication “MMV688533, a preclinical candidate to cure malaria” @ScienceTM Science Translational Medicine 21 Jul 2021: Vol. 13, Issue 603, eabg6013 https://stm.sciencemag.org/content/13/603/eabg6013 #malaria @MedsforMalaria @BIOASTER Abstract: The
- [Nouvelle publication dans Frontiers in Immunology](https://www.bioaster.org/bioaster-publishes-a-new-article-in-frontiers-in-immunology/) - BIOASTER en collaboration avec l’Hôpital Cochin et le consortium du projet REALISM (étude de la physiopathologie des patients en réanimation et sur les biomarqueurs), vient de publier l’article “Assessing the Functional Heterogeneity of Monocytes in Human Septic Shock: a Proof-of-Concept Microfluidic Assay of TNFα Secretion” dans Frontiers in Immunology. Cet article présente les résultats de
- [BIOASTER publishes a new article in Frontiers in Immunology .](https://www.bioaster.org/bioaster-publishes-a-new-article-in-frontiers-in-immunology/) - BIOASTER in collaboration with Cochin Hospital and the REALISM project consortium (study of the pathophysiology of intensive care patients and on biomarkers), has just published the article entitled “Assessing the Functional Heterogeneity of Monocytes in Human Septic Shock: a Proof- of-Concept Microfluidic Assay of TNFα Secretion ” in Frontiers in Immunology. This article presents the
- [DxPX Conference support to the Virtual US event in July](https://www.bioaster.org/dxpx-conference-support-to-the-virtual-us-event-in-july/) - BIOASTER is proud to support DxPx Conference Industry & Investor Conference, the unique international partnering conference with focus on #diagnostics, #PrecisionMedicine & research tools. During the virtual US event from July 27th - 31st, 2021, Xavier Morge, our CEO, will be pleased to tell you more about our #Diagnostics activities for #Microbiology and #infectiousdiseases : how we can co-invest to de-risk your R&D program from biomarker
- [Participation à la conférence DxPX  event en juillet](https://www.bioaster.org/dxpx-conference-support-to-the-virtual-us-event-in-july/) - BIOASTER est fier de soutenir DxPx Conference Industry & Investor Conference, la conférence de partenariat internationale unique axée sur le #diagnostic, la Medecine de Précision et les outils de recherche. Lors de l'événement virtuel aux États-Unis du 27 au 31 juillet 2021, Xavier Morge, notre PDG, sera ravi de vous en dire plus sur nos
- [3ème nouvelle note d'application cette année de l'unité Bioessais, Microsystèmes et Ingénierie Optique.](https://www.bioaster.org/3rd-application-note-from-bioassays-microsystems-and-optical-engineering/) - 3ème nouvelle note d'application cette année de l'unité Bioessais, Microsystèmes et Ingénierie Optique. A propos de l'ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) ou LATERAL FLOW ASSAY (LFA) : Integrated Diagnostic solutions. Ici : Note d'application BIMOP unit/ELISA ou LFA Pour (re)découvrir les autres: LABEL-FREE QUANTITATIVE PHASE IMAGING FOR SINGLE -CELL PHENOTYPING : Drug effect characterization form Digital
- [3rd application note from Bioassays, Microsystems and Optical engineering](https://www.bioaster.org/3rd-application-note-from-bioassays-microsystems-and-optical-engineering/) - 3rd new application note this year from Bioassays, Microsystems and Optical engineering unit. About ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) or LATERAL FLOW ASSAY (LFA) : Integrated Diagnostic solutions Here: Application note BIMOP unit/ELISA or LFA Have the look to the others: LABEL-FREE QUANTITATIVE PHASE IMAGING FOR SINGLE -CELL PHENOTYPING : Drug effect characterization form Digital In-Line
- [2 new application notes from Bioassays, Microsystems and Optical engineering](https://www.bioaster.org/new-application-note-from-bioassays-microsystems-and-optical-engineering/) - 2 new application notes from Bioassays, Microsystems and Optical engineering unit. LABEL-FREE QUANTITATIVE PHASE IMAGING FOR SINGLE -CELL PHENOTYPING : Drug effect characterization form Digital In-Line Holographic imaging of bacteria. Here: Application note BIMOP unit/ Holographic imaging DROPLET MICROFLUIDICS PLATFORM FOR SINGLE-CELL IMMUNE PROFILING: Neutrophils activation analysis bu elastase activity detection in droplets. Here: Application
- [2 nouvelles notes d'application de l'unité BIOESSAIS, MICROSYSTÈMES & INGÉNIERIE OPTIQUE](https://www.bioaster.org/new-application-note-from-bioassays-microsystems-and-optical-engineering/) - 2 nouvelles notes d'application de l'unité BIOESSAIS, MICROSYSTÈMES & INGÉNIERIE OPTIQUE Intitulée: LABEL-FREE QUANTITATIVE PHASE IMAGING FOR SINGLE -CELL PHENOTYPING : Drug effect characterization form Digital In-Line Holographic imaging of bacteria. Ici: Application note BIMOP unit/ holographic imaging DROPLET MICROFLUIDICS PLATFORM FOR SINGLE-CELL IMMUNE PROFILING: Neutrophils activation analysis bu elastase activity detection in droplets. Here: Applicaion
- [Call for a unique opportunity in antibiotic community: GNA NOW](https://www.bioaster.org/3813/) - Call for a unique opportunity in antibiotic community! The GNA NOW consortium (EU project) is looking for a novel antibiotic compound to progress to a clinical candidate. To find out more about the details of the call, make sure not to miss this webinar on May, 12th (10am): ???? https://bit.ly/3eTjGlM BIOASTER is actively taking part of
- [Call for a unique opportunity in antibiotic community: GNA NOW](https://www.bioaster.org/3813/) - Call for a unique opportunity in antibiotic community! The GNA NOW consortium (EU project) is looking for a novel antibiotic compound to progress to a clinical candidate. To find out more about the details of the call, make sure not to miss this webinar on May, 12th (10am): ???? https://bit.ly/3eTjGlM BIOASTER is actively taking part of
- [BIOASTER s'associe dans le lancement de L’Alliance Promotion Microbiote](https://www.bioaster.org/fr/bioaster-sassocie-dans-le-lancement-de-lalliance-promotion-microbiote/) - Elle est le fruit de l’union d’une quinzaine d’acteurs publics et privés engagés (instituts de recherche, entreprises, pôles de compétitivité), elle vise à promouvoir l’écosystème français impliqué dans la science émergente du Microbiote. Son objectif : construire un écosystème résilient positionnant la France comme leader européen dans le développement, la production et la commercialisation d’innovations
- [KALEIDO & BIOASTER: a successful completion](https://www.bioaster.org/kakeido-bioaster-a-successful-completion/) - Kaleido Biosciences and BIOASTER are glad to announce the successful completion of a collaborative project that provided new insights into ways Kaleido’s Microbiome Metabolic Therapies (MMT™) modulate the integrity and function of the gut epithelium through the gut microbiome. The cooperation of MetaGenoPolis, the INRAE center of microbiome research, significantly contributed to the success of this collaboration.
- [Appel à Partenariats](https://www.bioaster.org/fr/appel-a-partenariats/) - Opportunité unique pour faire valoir vos idées, vos projets, vos besoins et remettre le sujet des maladies infectieuses émergentes au cœur des sujets santé
- [KALEIDO & BIOASTER: a successful completion](https://www.bioaster.org/kakeido-bioaster-a-successful-completion/) - Kaleido Biosciences and BIOASTER are glad to announce the successful completion of a collaborative project that provided new insights into ways Kaleido’s Microbiome Metabolic Therapies (MMT™) modulate the integrity and function of the gut epithelium through the gut microbiome. The cooperation of MetaGenoPolis, the INRAE center of microbiome research, significantly contributed to the success of this collaboration.
- [Nouvelle collaboration avec PiLeJe Laboratoire](https://www.bioaster.org/new-collaboration-with-pileje-laboratoire/) - PiLeJe Laboratoire collabore avec BIOASTER pour étudier le potentiel santé d'une sélection de probiotiques Pileje Laboratoire, société française leader des compléments alimentaires à base de probiotiques en Europe et spécialisée dans les domaines des probiotiques, de la micronutrition et de la phytonutrition et BIOASTER, l'Institut français de recherche technologique en microbiologie appliquée, a annoncé aujourd'hui
- [New collaboration with PiLeJe Laboratoire](https://www.bioaster.org/new-collaboration-with-pileje-laboratoire/) - PiLeJe Laboratoire to collaborate with BIOASTER to investigate the health potential of a probiotic selection Pileje Laboratoire, a French company leader in probiotic-based dietary supplements in Europe and specialized in the fields of probiotics, micronutrition, and phytonutrition and BIOASTER, the French Technology Research Institute in applied microbiology, announced today the launch of a collaborative project
- [Partenariat Forum Santé Innovation Avril 2021 à Lyon](https://www.bioaster.org/fr/partenariat-forum-sante-innovation-avril-2021-a-lyon/) - #post_excerptSanté, Innovation,
- [Antimicrobials Program Highlights 2020](https://www.bioaster.org/antimicrobials-program-highlights-2020/) - We're happy to highlight some of the Antimicrobials Program achievements. If this should spark your curiosity we'll be happy to discuss with you in more detail
- [Antimicrobials Program Highlights 2020](https://www.bioaster.org/antimicrobials-program-highlights-2020/) - We're happy to highlight some of the Antimicrobials Program achievements. If this should spark your curiosity we'll be happy to discuss with you in more detail
- [L’IRT BIOASTER, passe l’épreuve de l’exercice « PPI »           ](https://www.bioaster.org/fr/lirt-bioaster-passe-lepreuve-de-lexercice-ppi/) - A la demande de la Préfecture, le @SDMIS69 –Service Départemental et Métropolitain d’Incendie et de Secours- conjointement avec la Police Nationale @PoliceNat69, a procédé jeudi 7 janvier à un exercice partiel de Sécurité Civile de type « PPI » pour Plan Particulier d’Intervention, au sein de l’Institut de Recherche Technologique BIOASTER à Lyon, au cœur du biodistrict de Gerland.
- [Bioaster 2021](https://www.bioaster.org/fr/bioaster-2021/) - L’année 2020, avec l’émergence soudaine et sévère du SARS-CoV-2, a montré que s’unir et collaborer est notre meilleure arme pour faire front commun contre une pandémie. Plus que jamais, la raison d’être de BIOASTER prend tout son sens en apportant aujourd’hui des solutions technologiques qui, mises au service des recherches et développements de produits de
- [BIOASTER 2021](https://www.bioaster.org/wishing-you-a-healthy-and-prosperous-new-year-2021/) - #post_excerpt2020, with the sudden and severe emergence of SARS-CoV-2, has shown that teaming-up and collaborating is our best option in coming together against a pandemic. More than ever, BIOASTER's purpose takes its full meaning by providing today technological solutions that, put at the service of our partners' research and product developments, will benefit patients tomorrow.
- [BIOASTER Microbiology Technology Research Institute announced a strategic partnership](https://www.bioaster.org/bioaster-microbiology-technology-research-institute-announced-a-strategic-partnership/) - BIOASTER, Université de Technologie de Compiègne, Hospices Civils de Lyon and bioMérieux formalize strategic collaboration to conduct Next Generation Sequencing technology evaluation in microbiology Lyon, December 2, 2020 - BIOASTER Microbiology Technology Research Institute announced a strategic partnership in the field of sequencing-based diagnostics in microbiology with the Université de Technologie de Compiègne (UTC), bioMérieux,
- [BIOASTER Microbiology Technology Research Institute announced a strategic partnership](https://www.bioaster.org/fr/bioaster-microbiology-technology-research-institute-announced-a-strategic-partnership/) - BIOASTER, Université de Technologie de Compiègne, Hospices Civils de Lyon and bioMérieux formalize strategic collaboration to conduct Next Generation Sequencing technology evaluation in microbiology Lyon, December 2, 2020 - BIOASTER Microbiology Technology Research Institute announced a strategic partnership in the field of sequencing-based diagnostics in microbiology with the Université de Technologie de Compiègne (UTC), bioMérieux,
- [REGISTER TO the next edition of I4ID 2020 in digital format](https://www.bioaster.org/register-to-the-next-edition-of-i4id-2020-in-digital-format/) - Register to the 4th edition of Immunotherapies & Innovations for Infectious Diseases congress! December 9th & 10th, 2020. This year the conference will be held only in digital and will largely address the current COVID-19 pandemics as well as other infectious diseases. The Scientific Committee has set-up a stimulating program focusing on Detection, Diagnosis, Clinical
- [Incriptions à la prochaine édition de I4ID 2020 à distance](https://www.bioaster.org/register-to-the-next-edition-of-i4id-2020-in-digital-format/) - Inscrivez vous à la 4ème édition du congrès Immunotherapies & Innovations for Infectious Diseases! Les 9 et 10 décembre 2020. Cette année la conférence sera donné uniquement à distance et abordera largement la pandémie actuelle du COVID-19 mais aussi des autres maladies infectieuses. Le comité scientifique a élaboré un programme stimulant et complet sur la
- [REGISTER TO th next edition of I4ID 2020 in digital format](https://www.bioaster.org/register-to-the-next-edition-of-i4id-2020-in-digital-format/) - Register to the 4th edition of Immunotherapies & Innovations for Infectious Diseases congress! December 9th & 10th, 2020. This year the conference will be held only in digital and will largely address the current COVID-19 pandemics as well as other infectious diseases. The Scientific Committee has set-up a stimulating program focusing on Detection, Diagnosis, Clinical
- [Automation of 16S Metagenomic Sequencing Library Preparation](https://www.bioaster.org/automation-of-16s-metagenomic-sequencing-library-preparation/) - Automation of 16S Metagenomic Sequencing Library Preparation Microbial composition analysis by 16S rRNA sequencing has become a standard practice. The preparation before the sequencing remains tedious and time-consuming. Automated library preparation for next-generation sequencing is a critical step in improving quality and cost-efficiency. In collaboration with Tecan, the Genomics and Transcriptomics technological unit of BIOASTER
- [Algorithms and microbes: BIOASTER joins other IRTs to accelerate the spread of artificial intelligence in health](https://www.bioaster.org/algorithms-and-microbes-bioaster-joins-other-irts-to-accelerate-the-spread-of-artificial-intelligence-in-health/) - With the exception of image analysis, artificial intelligence (AI) in the biomedical field is still in its infancy compared to other fields such as robotics or transport.
- [BioFilm Pharma and BIOASTER collaborate to accelerate the emergence of a new class of drugs to fight antibiotic resistance & chronic infections](https://www.bioaster.org/biofilm-pharma-and-bioaster-collaborate-to-accelerate-the-emergence-of-a-new-class-of-drugs-to-fight-antibiotic-resistance-chronic-infections/) - BioFilm Pharma and BIOASTER announced the signature of a research contract to address the challenge of antibiotic resistance. This collaboration will lead to the deciphering of the mode of action of a new class of drugs. BioFilm Pharma has identified a new generation of antimicrobials that are actives against the bacterial biofilms frequently observed during
- [Pre-print publication COVID19](https://www.bioaster.org/pre-print-publication-covid19-discovery-of-clinically-approved-drugs-capable-of-inhibiting-sars-cov-2-in-vitro-infection-using-a-phenotypic-screening-strategy-and-network-analysis-to-predict-their/) - Découverte de médicaments cliniquement approuvés capables d'inhiber l'infection in vitro par le SRAS-CoV-2 à l'aide d'une stratégie de dépistage phénotypique.
- [Open Call: Apply for TRANSVAC2 Vaccine Development Services](https://www.bioaster.org/open-call-apply-for-transvac2-vaccine-development-services/) - Developing a vaccine is a time-consuming and complex process, requiring a combination of specialized skills and technical capacities.
- [New collaboration with Kaleido Biosciences, BIOASTER and MetaGenoPolis to investigate the health potential of a novel class of therapies targeting the microbiome.](https://www.bioaster.org/new-collaboration-with-kaleido-biosciences-bioaster-and-metagenopolis-to-investigate-the-health-potential-of-a-novel-class-of-therapies-targeting-the-microbiome/) - Kaleido Biosciences va collaborer avec BIOASTER et MetaGenoPolis pour étudier le potentiel sanitaire d'une nouvelle classe de thérapies ciblant le microbiome.
- [BIOASTER est fier de partager cet article publié dans PLOS ONE.](https://www.bioaster.org/bioaster-is-proud-to-share-a-new-article-published-in-plos-one/) - Ce travail mené en collaboration avec Boehringer-Ingelheim, illustre nos capacités d’analyses en métagénomique et en culturomique appliquées à la santé animale.
- [BIOASTER & GENCOVERY](https://www.bioaster.org/bioaster-gencovery/) - BIOASTER premier actionnaire avec ses deux co-fondateurs Adama OUATTARA et Wassim ABOU-JAOUDE de Gencovery.
- [Une nouvelle publication sur la maladie de CHAGAS a été publiée dans Metabolomics.](https://www.bioaster.org/a-new-publication-about-chagas-disease-has-been-released-this-summer-in-metabolomics/) - Une nouvelle publication sur la maladie de CHAGAS a été publiée dans Metabolomics. Découvrez la publication.
- [REGISTRATION I4ID2019](https://www.bioaster.org/registration-opens-to-the-3rd-i4id-2019-congress/) - Registration to the 3rd Immunotherapies & Innovation for Infectious Diseases (I4ID2019) that will be held on December 4-5, 2019 in Lyon, France.
- [SMART OMICS: Expertises@BIOASTER new video online!](https://www.bioaster.org/smart-omics-expertisesbioaster-new-video-online/) - Have a look to our brand new video online on EXPERTISES @BIOASTER's series about SMART OMICS.
- [Pre-print publication COVID19](https://www.bioaster.org/pre-print-publication-covid19-discovery-of-clinically-approved-drugs-capable-of-inhibiting-sars-cov-2-in-vitro-infection-using-a-phenotypic-screening-strategy-and-network-analysis-to-predict-their/) - Discovery of clinically approved drugs capable of inhibiting SARS-CoV-2 in vitro infection using a phenotypic screening strategy and network-analysis.
- [Open Call: Apply for TRANSVAC2 Vaccine Development Services](https://www.bioaster.org/open-call-apply-for-transvac2-vaccine-development-services/) - Le développement d'un vaccin est un processus long et complexe, qui nécessite une combinaison de compétences spécialisées et de capacités techniques.
- [@BIOASTER, nous sommes fiers que les résultats de l’un de nos projets permettent aujourd’hui de lancer un autre programme ambitieux, par @mologic et @institutpasteur de Dakar, pour mieux combattre #ebola #maladiesinfectieuses](https://www.bioaster.org/fr/bioaster-nous-sommes-fiers-que-les-resultats-de-lun-de-nos-precedent-projets-permettent-aujourdhui-de-lancer-un-autre-programme-ambitieux-par-mologic-et-institutpasteur-de-dakar/) - Les résultats de l’un de nos projets permettent aujourd’hui de lancer un autre programme ambitieux pour mieux combattre lrd maladies infectieuses.
- [The last strategic committee of the FAME project conducted in collaboration between BIOASTER and MaaT Pharma took place Friday, April 10, 2020.](https://www.bioaster.org/the-last-strategic-committee-of-the-fame-project-conducted-in-collaboration-between-bioaster-and-maat-pharma-took-place-friday-april-10-2020/) - Through this collaboration, BIOASTER and MaaT Pharma illustrate once again the dynamism and quality of the French ecosystem in the promising field of microbiome
- [A new publication about Chagas disease this november in the “Journal of Medicinal Chemistry”](https://www.bioaster.org/a-new-publication-about-chagas-disease-this-november-in-the-journal-of-medicinal-chemistry/) - A new publication about #Chagas disease has been released on November in Journal of Medicinal Chemistry. Entitled “Chagas Disease Drug Discovery.
- [Venez nous rencontrer lors de la 1ère conférence DxPx - Diagnostics Partnering puis à MEDICA à Düsseldorf du 18 au 20 novembre 2019](https://www.bioaster.org/meet-us-at-the-1st-dxpx-diagnostics-partnering-conference-in-dusseldorf-on-november-from-18th-to-20th/) - Venez nous rencontrer lors de la 1ère édition de la conférence DxPx - Diagnostics Partnering à Düsseldorf, Allemagne, le 18 novembre 2019. Sara Fröjdö, responsable des partenariats du programme Diagnostic chez BIOASTER, participera au 1er événement de partenariat DxPx Diagnostics puis chez MEDICA la semaine du 18 novembre à Düsseldorf, en Allemagne. Elle serait heureuse
- [@BIOASTER : en ordre de marche pour prendre part au combat contre le Covid-19](https://www.bioaster.org/bioaster-in-working-order-to-take-part-in-the-fight-against-the-covid-19/) - A partir d’aujourd’hui, nos activités courantes en cours au sein de l’Institut ont été encore réduites, voire même totalement stoppées pour certaines : pour faciliter le travail des hôpitaux et centre de soins en diminuant nos besoins en ressources vitales aujourd’hui pour eux et leur patients. pour pouvoir disposer du maximum de forces et de ressources
- [Nous sommes très heureux d'annoncer une nouvelle collaboration avec Takeda](https://www.bioaster.org/we-are-very-pleased-to-announce-a-new-collaboration-with-takeda/) - BIOASTER a conclu un accord de collaboration avec Takeda pour développer et valider de nouvelles approches basées sur le microbiome dans le contexte des actifs de Takeda au stade clinique pour le traitement des maladies gastro-intestinales. Cette collaboration avec Takeda est une étape importante pour BIOASTER dans la démonstration de sa capacité à soutenir le
- [@BIOASTER: in working order to take part in the fight against the Covid-19](https://www.bioaster.org/bioaster-in-working-order-to-take-part-in-the-fight-against-the-covid-19/) - As of today, our current ongoing activities within the Institute have been further reduced, or even completely stopped in order to: facilitate the work of hospitals and care centers by reducing our need for vital resources today for them and their patients. be able to have the maximum technological strength and resources for all requests
- [Dr Nathalie Garçon, Directrice Générale et Scientifique de BIOASTER reçoit l’insigne d’Officier de la Légion d’honneur](https://www.bioaster.org/fr/dr-nathalie-garcon-directrice-generale-et-scientifique-de-bioaster-recoit-linsigne-dofficier-de-la-legion-dhonneur/) - Nathalie Garçon, Directrice Générale et Directrice scientifique de l’Institut de Recherche Technologique BIOASTER a reçu le 9 septembre 2020 l’insigne d’Officier de la Légion d’honneur des mains d’Alain Mérieux.
- [SMART OMICS: Expertises@BIOASTER nouvelle vidéo en ligne!](https://www.bioaster.org/smart-omics-expertisesbioaster-new-video-online/) - Découvrez la vidéo sur les EXPERTISES @BIOASTER à propos des SMART OMICS. L'équipe du pôle OMICS de BIOASTER vous présente le concept de SMART OMICS.
- [BIOASTER & GENCOVERY](https://www.bioaster.org/bioaster-gencovery/) - BIOASTER first shareholder with its two co-founders Adama OUATTARA and Wassim ABOU-JAOUDE of Gencovery. Wishing success to the first BIOASTER start-up. Gencovery provides cutting-edge software based on digital organisms for biotechnology and pharma industry.
- [Inscriptions I4ID 2020! La fin des inscriptions early bird repoussée au 30 Octobre!](https://www.bioaster.org/fr/registration-i4id-2020-deadline-early-bird-rate-extended-to-october-30th/) - Inscriptions au prochain congrès I4ID 2020La fin des inscriptions early bird repoussée au 30 Octobre! Inscriptions, Programme et information sponsor: https://www.i4id.org/ Depêchez vous!
- [Nouvelle publication BIOASTER sur Poultry Sciences à décourvir](https://www.bioaster.org/fr/nouvelle-publication-bioaster-sur-poultry-sciences-a-decourvir/) - This #Multiomics study, combining #Metabolomics and #Transcriptomics, aims at deciphering the pathways involved in the immune response induced by an immune-stimulant in chickens. This work is part of a collaboration with @Boehringer_AH (a founding member of @Bioaster) for the development of an avian toolbox, dedicated to the screening of immune-stimulant candidates to be used as
- [Nouvelle publication dans Microbiology Resource Announcements® (MRA)](https://www.bioaster.org/fr/new-publication-on-microbiology-resource-announcements-mra/) - Bioaster vient de publier les génomes bactériens de son modèle de souris gnotobiotique (GM15), mis au point pour produire un nouveau modèle standardisé de souris avec un microbiote intestinal contrôlé et simplifié au fin d' assurer une meilleure reproductibilité et robustesse des études précliniques en limitant la variabilité due à la fluctuation de la composition
- [BIOASTER is proud to share a new article published in PLOS ONE.](https://www.bioaster.org/bioaster-is-proud-to-share-a-new-article-published-in-plos-one/) - “Caecal microbiota compositions from 7-day-old chicks reared in high-performance and low-performance industrial farms and systematic culturomics to select strains with anti-Campylobacter activity”. See the article This work carried out in collaboration with Boehringer-Ingelheim, (a founding member of BIOASTER) illustrates our capacities to perform metagenomics and culturomic analyses applied to animal health.
- [Découvrez notre nouvelle publication @BIOASTER dans @NatureProtocols.](https://www.bioaster.org/discover-our-new-bioaster-publication-in-natureprotocols/) - Nous avons développé une technologie microfluidique#microfluidics en gouttelettes pour mesurer la cinétique de la sécrétion de protéines #proteinsecretion à partir de cellules uniques #singlecells. Cette technologie a été utilisée avec succès pour caractériser l'anergie des monocytes chez les patients ayant subi un choc septique. Lien PDF
- [Discover our new @BIOASTER publication in @NatureProtocols.](https://www.bioaster.org/discover-our-new-bioaster-publication-in-natureprotocols/) - A droplet #microfluidics technology has been developed to measure #proteinsecretion kinetics from #singlecells. This technology has been successfully used to characterize monocyte anergy in septic shock patients. SharedIt link
- [The last strategic committee of the FAME project conducted in collaboration between BIOASTER and MaaT Pharma took place Friday, April 10, 2020.](https://www.bioaster.org/the-last-strategic-committee-of-the-fame-project-conducted-in-collaboration-between-bioaster-and-maat-pharma-took-place-friday-april-10-2020/) - Le dernier comité stratégique du projet FAME mené en collaboration entre BIOASTER et MaaT Pharma a eu lieu le vendredi 10 avril 2020.
- [@BIOASTER, we are proud when results of one of our former collaborative projects allow the launch of another accelerated program serving global health.](https://www.bioaster.org/bioaster-we-are-proud-when-results-of-one-of-our-former-collaborative-projects-allow-the-launch-of-another-accelerated-program-serving-global-health/) - @BIOASTER, we are proud when results of one of our former collaborative projects allow the launch of another accelerated program serving global health.
- [New collaboration Gustave Roussy – IRT BIOASTER](https://www.bioaster.org/new-collaboration-gustave-roussy-irt-bioaster/) - "Fishing for success: Cancer microbiome-targeted culturomics to extract the most immunogenic commensals". The complete press release here.
- [Nouvelle collaboration Gustave Roussy - IRT BIOASTER](https://www.bioaster.org/new-collaboration-gustave-roussy-irt-bioaster/) - « Culturomique ciblée du microbiote des patients atteints de cancer pour isoler les commensaux les plus immunogènes » Communiqué de presse ici
- [L’Etat renouvelle sa confiance à l’IRT BIOASTER](https://www.bioaster.org/fr/letat-renouvelle-sa-confiance-a-lirt-bioaster/) - BIOASTER se félicite du réengagement fort et clair de l’Etat auprès des IRT pour développer et dynamiser la recherche technologique française. Cet accompagnement va donner à l’Institut de Recherche Technologique en microbiologie les moyens, dans la durée, de participer encore plus activement à la lutte contre les maladies infectieuses. « Cet engagement de l’Etat est la
- [The French Government renews its confidence in IRT BIOASTER](https://www.bioaster.org/the-french-government-renews-its-confidence-in-irt-bioaster/) - BIOASTER welcomes the renewal of the support of the French Government. The Government thus strongly and clearly expresses its confidence in IRTs to develop and boost French technological research. This further support will give us, as the only Technological Research Institute in Microbiology, the means to contribute even more actively to the global fight against
- [We are very pleased to announce a new collaboration with Takeda](https://www.bioaster.org/we-are-very-pleased-to-announce-a-new-collaboration-with-takeda/) - BIOASTER has entered into a collaboration agreement with Takeda to develop and validate new microbiome-based approaches in the context of Takeda’s clinical-stage assets for the treatment of gastrointestinal diseases. This collaboration with Takeda is an important step for BIOASTER in demonstrating its ability to support the clinical development of promising therapies with innovative approaches based
- [For a new kind of fight](https://www.bioaster.org/for-a-new-kind-of-fight/) - A Covid-19 learning By Nathalie Garçon, CEO/CSO BIOASTER The current crisis reminds us today of the absolute and universal need to prepare in advance for such epidemics, which no one can guarantee will never happen again. History has also shown that it can be difficult to predict, as soon as a new pathogen emerges,
- [Philippe Archinard réélu Président de BIOASTER](https://www.bioaster.org/fr/philippe-archinard-reelu-president-de-bioaster/) - Le Conseil d’Administration de la Fondation de Coopération Scientifique, l’IRT BIOASTER, s’est tenu vendredi 27 mars 2020. L’ensemble du Conseil d’Administration a réélu Philippe Archinard pour un troisième mandat de 3 ans, Président de BIOASTER. « Je remercie le Conseil d’Administration de m’accorder sa confiance pour ce nouveau mandat qui débute dans un environnement sanitaire et
- [Se préparer aux luttes d'un nouveau genre](https://www.bioaster.org/for-a-new-kind-of-fight/) - A Covid-19 learning Par Dr Nathalie Garçon, CEO/CSO BIOASTER La crise actuelle nous rappelle aujourd’hui la nécessité absolue et universelle de se préparer à l’avance à de telles épidémies, dont personne ne peut garantir qu’elles ne pourront plus se produire. L’histoire a montré aussi qu’il peut être difficile d’appréhender, dès l’émergence d’un nouveau pathogène,
- [INFORMATION BIOASTER COVID-19](https://www.bioaster.org/fr/information-bioaster-covid-19/) - Nous traversons une crise majeure et inédite qui implique de repenser drastiquement nos modes de vie et de travail pour ralentir l’épidémie qui est désormais omniprésente, permettre à notre système de santé de réaliser au mieux sa mission de soins et préserver les plus fragiles d’entre nous. Une telle situation nous ramène à notre "raison
- [BIOASTER COVID-19 INFORMATION](https://www.bioaster.org/bioaster-covid-19-information/) - We are going through a major and unprecedented crisis, which involves drastically rethinking our lifestyles and work to slow down the epidemic, which is now ubiquitous, allow our health system to best achieve its mission of care and preserve the most fragile of us. Such a situation brings us back to our "raison d'être". BIOASTER
- [Governance evolution at BIOASTER, microbiology technology institute](https://www.bioaster.org/governance-evolution-at-bioaster-microbiology-technology-institute/) - Lyon, April 20th, 2015: BIOASTER microbiology technology institute announced that its board of directors has decided during his 2nd of April plenary session.
- [Kick Off meeting: GNA-NOW a new European project](https://www.bioaster.org/kick-off-meeting-gna-now-a-new-european-project/) - BIOASTER teams are currently in Utrecht for the kick-off meeting of the European project GNA-NOW, part of the AMR Accelerator Programme of IMI 2.
- [Greetings from BIOASTER](https://www.bioaster.org/greetings-from-bioaster/) - All members of our team from our institute BIOASTER wishes you a happy new year for 2020 !
- [BIOASTER obtient la certification NGO Source](https://www.bioaster.org/bioaster-obtains-certification-ngo-source/) - L’IRT se donne ainsi les moyens de développer de nouveaux partenariats avec les fondations américaines investies dans la lutte contre les maladies infectieuses La Fondation BIOASTER a reçu une « Equivalency Determination » qui lui permet d’être reconnue comme un organisme à but non lucratif aux États-Unis d’Amérique. Cette équivalence a été obtenue à la demande d’une
- [Registrations still opened for I4ID 2019!](https://www.bioaster.org/registrations-still-open-for-i4id-2019/) - Don't forget to register to the next I4ID 2019 congress! Registrations to the 3rd Immunotherapies & Innovation for Infectious Diseases (I4ID2019) are still opened. The congress will be held on December 4-5, 2019 in Lyon, France and organized by MabDesign, BIOASTER and Lyonbiopôle. https://i4id.org/register/ The purpose of these two-day congress, jointly organized by @BIOASTER, @MabDesign
- [New collaboration with Kaleido Biosciences, BIOASTER and MetaGenoPolis to investigate the health potential of a novel class of therapies targeting the microbiome.](https://www.bioaster.org/new-collaboration-with-kaleido-biosciences-bioaster-and-metagenopolis-to-investigate-the-health-potential-of-a-novel-class-of-therapies-targeting-the-microbiome/) - Kaleido Biosciences to collaborate with BIOASTER and MetaGenoPolis to investigate the health potential of a novel class of therapies targeting the microbiome. Kaleido Biosciences, a U.S.-based clinical-stage healthcare company, and BIOASTER, the French Technology Research Institute in applied microbiology, announced today the initiation of a collaborative project aiming to evaluate the immunomodulatory and homeostatic potential
- [BioFilm Pharma et BIOASTER collaborent afin d’accélérer la mise sur le marché d’une première génération d’antibiofilm pour lutter contre les infections chroniques](https://www.bioaster.org/biofilm-pharma-and-bioaster-collaborate-to-accelerate-the-emergence-of-a-new-class-of-drugs-to-fight-antibiotic-resistance-chronic-infections/) - BioFilm Pharma et BIOASTER ont annoncé aujourd’hui la signature d’un contrat de recherche pour l’identification du mode d’action d’une nouvelle classe de médicaments destinés à lutter contre la résistance aux antibiotiques. BioFilm Pharma a identifié les premiers antibiofilms, une nouvelle génération d’antimicrobiens actifs sur le biofilm bactérien à l’origine des maladies chroniques. Ce partenariat mobilisera
- [BIOASTER obtient une subvention pour le développement d'un diagnostic rapide des maladies tropicales négligées](https://www.bioaster.org/bioaster-awarded-grant-for-the-development-of-rapid-diagnostics-for-neglected-tropical-diseases/) - BIOASTER reçoit une subvention de 885 000 $ de la Fondation Bill & Melinda Gates pour développer un diagnostic rapide avancé de l'onchocercose avec Mologic Ltd. BIOASTER, a annoncé aujourd'hui avoir reçu une subvention dans le domaine du diagnostic des maladies tropicales négligées (MTN) de la Fondation Bill & Melinda Gates. L'objectif du projet est
- [BIOASTER Awarded Grant for the Development of Rapid Diagnostics for Neglected Tropical Diseases](https://www.bioaster.org/bioaster-awarded-grant-for-the-development-of-rapid-diagnostics-for-neglected-tropical-diseases/) - @BIOASTER receives $885K grant from the Bill & Melinda Gates Foundation @gatesfoundation to develop #Onchocerciasis advanced rapid #diagnostic with @mologic Ltd. BIOASTER, today announced it has received a grant in the field of diagnosis of Neglected Tropical Diseases (NTD) from the Bill & Melinda Gates Foundation. The goal of the project is to develop advanced
- [Watch our new video about SMART OMICS - Expertises @BIOASTER](https://www.bioaster.org/wathch-our-new-video-about-smart-omics/) - #OmicsTechnologies are today in the heart of early research in #microbiology and #InfectiousDiseases. To leverage these #technologies in applied research, we need to develop new solutions corresponding to industrial processes and needs. In this context, @BIOASTER has developed and implemented the concept of SMART Omics, for the application of #omics technologies in R&D, in our
- [Application Note from OMICs Hub Metabolomics](https://www.bioaster.org/application-note-from-omics-hub-metabolomics/) - APPLICATION NOTE from the OMICs HUB about inter-individual heterogeneity in clinical metabolomics studies: Assessment of inter-individual NMR/MS metabolic signatures variability in plasma of a heterogeneous group of healthy volunteers – impact for biomarkers discovery. All information here: ApplicationNote-OMICsHub-Metabolomics-01
- [Meet us at the 1st DxPx – Diagnostics Partnering conference in Dusseldorf on November from 18th to 20th](https://www.bioaster.org/meet-us-at-the-1st-dxpx-diagnostics-partnering-conference-in-dusseldorf-on-november-from-18th-to-20th/) - Meet us at the first DxPx – Diagnostics Partnering conference in Dusseldorf on November 18th Sara Fröjdö, Partnership Manager at BIOASTER, will be present at the 1st DxPx Diagnostics Partnering event as well as at MEDICA the week of November 18th in Dusseldorf, Germany. She would be happy to meet with you to explain our
- [Les inscriptions sont ouvertes pour le 3ème congrès I4ID 2019](https://www.bioaster.org/registration-opens-to-the-3rd-i4id-2019-congress/) - Les inscriptions pour la 3ème édition du Programme Immunothérapie et Innovation pour les maladies infectieuses (I4ID2019) auront lieu les 4 et 5 décembre 2019 à Lyon, en France. https://i4id.org/register/ Ce congrès de deux jours, organisé conjointement par @BIOASTER, @MabDesign et @ Lyonbiopôle, a pour objectif de favoriser les interactions entre les industries pharmaceutiques, les laboratoires
- [Regardez notre nouvelle vidéo SMART OMICS - Expertises@BIOASTER](https://www.bioaster.org/wathch-our-new-video-about-smart-omics/) - Les technologies omiques sont aujourd’hui au cœur de la recherche fondamentale dans les domaines de la microbiologie et des maladies infectieuses. Pour implémenter ces technologies en recherche appliquée, nous devons développer de nouvelles solutions répondant aux besoins et processus industriels. Dans ce contexte, BIOASTER a développé et mis en place le concept de SMART Omics,
- [BIOASTER is increasing its bioinformatic capabilities by signing a strategic partnership with IN2P3 Computing Center (CNRS)](https://www.bioaster.org/bioaster-is-increasing-its-bioinformatic-capabilities-by-signing-a-strategic-partnership-with-in2p3-computing-center-cnrs/) - Mass data storage and subatomic physics and astrophysics computing power are now being made available to the field of health-related and infectious disease microbiology.
- [Collaborative study for a rapid diagnostic test for Ebola Virus Disease by BIOASTER and FUJIFILM Corporation](https://www.bioaster.org/collaborative-study-for-a-rapid-diagnostic-test-for-ebola-virus-disease-by-bioaster-and-fujifilm-corporation/) - BIOASTER announced that it has confirmed and started a collaboration for the study of an Ebola Virus Disease (EVD) rapid diagnostic system with FUJIFILM Corporation.
- [BIOASTER announces Hepatitis B Collaboration with Janssen and the Cancer Center of Lyon (CRCL).](https://www.bioaster.org/bioaster-announces-hepatitis-b-collaboration-with-janssen-and-the-cancer-center-of-lyon-crcl/) - BIOASTER announces Hepatitis B Collaboration with Janssen and the Cancer Center of Lyon (CRCL). Objective of the collaboration: bring a predictive model for the development of novel therapies.
- [BIOASTER demonstrates Its know-how on generation, production and purification of nanoparticles.](https://www.bioaster.org/bioaster-demonstrates-its-know-how-on-generation-production-and-purification-of-nanoparticles/) - Within recent years, the development of genetically engineered recombinant VLPs has accelerated the need for new, improved downstream processes.
- [« Collaboration today is key both for knowledge and technology innovation issues » Nathalie Garçon @biovisionforum 2016](https://www.bioaster.org/collaboration-today-is-key-both-for-knowledge-and-technology-innovation-issues-nathalie-garcon-biovisionforum-2016/) - « Collaboration today is key both for knowledge and technology innovation issues » Nathalie Garçon @biovisionforum 2016
- [2016 IRT’s Forum will take place in Paris on october, more infos to come](https://www.bioaster.org/2016-irts-forum-will-take-place-in-paris-on-october-more-infos-to-come/) - 2016 IRT’s Forum will take place in Paris on october, more infos to come
- [BIOASTER will be at the BIO international convention, june 6-9, 2016 in San Francisco](https://www.bioaster.org/bioaster-will-be-at-the-bio-international-convention-june-6-9-2016-in-san-francisco/) - BIOASTER will be at the BIO international convention, june 6-9, 2016 in San Francisco.
- [Welcome to our new diagnostics program manager, Philippe Leissner](https://www.bioaster.org/welcome-to-our-new-diagnostics-program-manager-philippe-leissner/) - Welcome to our new diagnostics program manager, Philippe Leissner
- [Visit : We had the pleasure to welcome Sir Julian King, British Ambassador to France for a visit of BIOASTER headquarters, on Monday 25th of April](https://www.bioaster.org/visit-we-had-the-pleasure-to-welcome-sir-julian-king-british-ambassador-to-france-for-a-visit-of-bioaster-headquarters-on-monday-25th-of-april/) - Visit : We had the pleasure to welcome Sir Julian King, British Ambassador to France for a visit of BIOASTER headquarters, on Monday 25th of April
- [Nathalie Garçon's Interview](https://www.bioaster.org/nathalie-garcons-interview/) - Nathalie Garçon, audio interview on the blog of Neomed institute (Canada) « Bioaster, Neomed : Same Objective, Similar Approach, Some Differences » : http://blog.neomed.ca
- [BIOASTER has been pleased to welcome a delegation of the Brookings Institution invited by Mister Gérard COLLOMB](https://www.bioaster.org/bioaster-has-been-pleased-to-welcome-a-delegation-of-the-brookings-institution-invited-by-mister-gerard-collomb/) - Today, BIOASTER had the honor to present the Biodistrict and the model for innovation of the TRI to a delegation of the Brookings Institution invited by Mr Gérard COLLOMB.
- [BIOASTER at JOBIM](https://www.bioaster.org/bioaster-at-jobim/) - Our bioIT specialists team was there during the 3 days of the conference and was pleased to answer the questions of the curious scientists.
- [BIOASTER welcomes the Australian government's Innovation Delegation.](https://www.bioaster.org/bioaster-welcomes-the-australian-governments-innovation-delegation/) - BIOASTER welcomes an Australian government's delegation to visit our premises.
- [BIOASTER, partner with the European Project TRANSVAC2 coordinated by the European Vaccine Initiative (EVI)](https://www.bioaster.org/bioaster-partner-with-the-european-project-transvac2-coordinated-by-the-european-vaccine-initiative-evi/) - The European Commission announces the start of the TRANSVAC2 project, coordinated by the European Vaccines Initiative (EVI) in the context of the Horizon 2020 Program.
- [International Society for Vaccines Oct 5th-7th](https://www.bioaster.org/international-society-for-vaccines-oct-5th-7th/) - Nathalie Garçon, CEO / CSO will introduce BIOASTER at International Society of Vaccines, Plenary Session " Public Private Partnerships" Oct sat 7thPartnerships" Oct sat 7th
- [Visit of Singapour ambassador](https://www.bioaster.org/visit-of-singapour-ambassador/) - This morning, BIOASTER welcomed the Singapore Ambassador to France, Mr Zainal Arif MANTAHA, for a very interesting meeting. Dr. Cyril Guyard leads the visit of our HQ.
- [Press Release Collaborative Project MOSAIC w SANOFI PASTEUR](https://www.bioaster.org/press-release-collaborative-project-mosaic-w-sanofi-pasteur/) - BIOASTER announces today, the initiation of a collaborative project aiming at improving the safety and immunogenicity of adjuvants included in the composition of new candidate vaccines. MOSAIC (MOlecular Signatures of Adjuvanted vaccIne Candidates) is a unique opportunity for BIOASTER to capitalize on its translational high-throughput omics pipelines relying on integrated transcriptomics, metabolomics and high-dimensional cell
- [New video releases: Technologies designed by BIOASTER](https://www.bioaster.org/new-video-releases-technologies-designed-by-bioaster/) - Have a look to our new online video about technologies designed by BIOASTER: Discover the technology Met-SAMoA®
- [New publication - May 2018: An innovative platform on nanoparticles](https://www.bioaster.org/new-publication-may-2018-an-innovative-platform-on-nanoparticles/) - New publication in Vaccine May 2018, based on an innovative platform on nanoparticles. The Protein & Expression system engineering Unit has developed a new nanoparticle carrier system that enables simultaneous epitope surface display and heterologous protein loading (patent WO2017182760 A1). Immunogenicity studies revealed antibody responses against both the surface epitope and the loaded cargo protein.
- [BIOASTER at Institut Pasteur's course!](https://www.bioaster.org/bioaster-at-institut-pasteurs-course/) - BIOASTER participates in the Pasteur course Christophe Vedrine (Biological Microsystems and Advanced Optics engineering unit) and Fabrice Porcheray (Immunomonitoring Unit) had the opportunity to give a presentation as part of the Pasteur course "Innate Immunity and Infectious Diseases" organized by Jean-Marc Cavaillon and Daniel Scott-Agara. This lecture, presented to an international group of students, focused
- [BIOASTER is proud to be "co-author" of this paper in Nature Communications](https://www.bioaster.org/bioaster-is-proud-to-be-co-author-of-this-paper-in-nature-communications/) - BIOASTER is proud to be "co-author" of this paper in Nature Communications. "A modular transcriptional signature identifies phenotypic heterogeneity of human tuberculosis infection"
- [June 26th&27th, BIOASTER invited to join a Brazilian public-private initiative network](https://www.bioaster.org/june-26th27th-bioaster-invited-to-join-a-brazilian-public-private-initiative-network/) - June 26th&27th 2018, BIOASTER invited to join a Brazilian public-private initiative network.
- [New publication about BIOFILM](https://www.bioaster.org/new-publication-about-biofilm/) - A new publication about BIOFILM has been released on August 29th on Nature/Scientific reports. Entitled "A steam-based method to investigate biofilm", it has been co-written by Régis Villet from BIOASTER. Well done! Get the paper here: A steam-based method to investigate biofilm
- [BIOASTER @The Human Microbiome conference September, 2018](https://www.bioaster.org/bioaster-the-human-microbiome-conference-september-2018/) - Bioaster will be at «The Human Microbiome» conference, with one poster presenting LUMI-seq™, our method for reconstructing near full-length 16S rRNA genes using Illumina short reads. The Human microbiome conference, 16 - 19 Sep 2018 @EMBL Heidelberg, Germany
- [New video release : ANOXIC](https://www.bioaster.org/new-video-release-anoxic/) - Discover another Technologies designed by BIOASTER: ANOXIC platform! Based at BIOASTER Paris's premises, the ANOXIC platform is a set of expertise and equipment specially developed to handle anaerobic strains of microbiota in a controlled-atmosphere cell sorter. https://youtu.be/vV1d4n2r6gc Enjoy!
- [BIOASTER @'the virus-Like Particle & Nanoparticle Vaccines' congress in Bern](https://www.bioaster.org/bioaster-the-virus-like-particle-nanoparticle-vaccines-congress-in-bern/) - Dr Bettina Werle, Head of Protein and Expression System Engineering Unit at BIOASTER, will be attending the Virus-Like Particle & Nanoparticle Vaccines congress.
- [BIOASTER acquired the new BD FACSymphony flow cytometer](https://www.bioaster.org/bioaster-acquired-the-new-bd-facsymphony-flow-cytometer/) - BIOASTER acquired the new BD FACSymphony flow cytometer The BD FACSymphony class of instruments are SORP (Special Order Research Products) flow cytometers equipped with 5 lasers and designed to generate data of up to 30 parameters for each cell. The BIOASTER Immunomonitoring facility in Lyon is hosting one of the three Symphony available in France.
- [BIOASTER @BIO-EUROPE® 2018 Copenhague](https://www.bioaster.org/bioaster-bio-europe-2018-copenhague/) - BIOASTER will be at BIO-Europe® 2018 Copenhague November 5–7, 2018. Start requesting meetings via the partneringONE® platform! : https://ebdgroup.knect365.com/bioeurope/about-bio-europe We look forward to meeting you and discussing potential future collaboration in applied microbiology!
- [BIOASTER @ LBP's collaborative days, the 10/18/2018 at Grenoble !](https://www.bioaster.org/bioaster-lbps-collaborative-days-the-10-18-2018-at-grenoble/) - BIOASTER will be at the Lyon BioPôle's collaborative days, the 10/18/2018 at Grenoble, France ! Come and visite us there ! A table talk on macrobiota will be managed by our Head of Microbiota Program. LPB : https://lyonbiopole.com/journee-collaborative-2018
- [BIOASTER will be @ ICCMG (International Conference on Clinical Metagenomics), the 18/19 October 2018 at Geneva !](https://www.bioaster.org/bioaster-will-be-iccmg-international-conference-on-clinical-metagenomics-the-18-19-october-2018-at-geneva/) - Come and meet us at the ICCMG (International Conference on Clinical Metagenomics) the 18/19 October 2018 at Geneva, Switzerland.
- [Accelerate VACCINE European research: BIOASTER reinforces its participation to TRANSVAC2 European Project.](https://www.bioaster.org/accelerate-vaccine-european-research-bioaster-reinforces-its-participation-to-transvac2-european-project/) - Accelerate VACCINE European research: BIOASTER reinforces its participation to TRANSVAC2 European Project.
- [MEET BIOASTER at PEGS Europe congress from November 12th to 16th, 2018 @Lisbon, Portugal](https://www.bioaster.org/meet-bioaster-at-pegs-europe-congress-from-november-12th-to-16th-2018-lisbon-portugal/) - Dr Supanee Potisopon, Research scientist at Protein and Expression System Engineering Unit at BIOASTER, will be attending PEGS Europe congress, in Lisbon next week.
- [Novel Antimicrobials and AMR Diagnostics 2019](https://www.bioaster.org/novel-antimicrobials-and-amr-diagnostics-2019/) - Bioaster will attend the upcoming Novel Antimicrobials and AMR Diagnostics 2019. Come and meet with our partnership team in Berlin on March 14th and 15th! More information : https://amr-conference.com/
- [FunHoMic: Marie Sklodowska-Curie Innovative Training Network](https://www.bioaster.org/funhomic-marie-sklodowska-curie-innovative-training-network/) - FunHoMic is a Marie Skłodowska-Curie Innovative Training Network that will train 13 Early Stage Researchers and decipher fungus-host-microbiota interplay to improve the management of fungal infections. In their research projects, FunHoMic ESRs will tackle the interaction between pathogenic fungi, the host and the microbiota in order to identify novel biomarkers (fungal or host genetic polymorphisms,
- [A new High Resolution Mass Spectrometer Q Exactive HF](https://www.bioaster.org/nouveau-spectrometre-de-masse-haute-resolution-q-exactive-hf/) - BIOASTER Omics’ Hub acquired a new High Resolution Mass Spectrometer Q Exactive HF. The Thermo Scientific™ Q Exactive™ HF hybrid quadrupole-Orbitrap mass spectrometer features an ultra-high-field Orbitrap analyzer which doubles its speed and resolution. This new MS instrument will complete our existing park, in order to increase our analytical capacity. But it will also offer
- [Participation to Keystone Conference: " Microbiome: Chemical Mechanisms and Biological Consequences" 2019](https://www.bioaster.org/participation-to-keystone-conference-microbiome-chemical-mechanisms-and-biological-consequences-2019/) - BIOASTER will participate to the next Keystone conference intitled 'Microbiome: Chemical Mechanisms and Biological Consequences’.
- [Next edition #3 I4ID Congress](https://www.bioaster.org/next-edition-3-i4id-congress/) - The next edition of I4ID Congress #3 will take place on December 4th and 5th, 2019 in Lyon France.
- [BIOASTER will animate next Monday 20th may 2019, at 4.5pm, a workshop dedicated to BioTracs-MIMOSA at the RFMF Congress, to present its design and functionalities, and will also present a poster.](https://www.bioaster.org/bioaster-will-animate-next-monday-20th-may-2019-at-4-5pm-a-workshop-dedicated-to-biotracs-mimosa-at-the-rfmf-congress-to-present-its-design-and-functionalities-and-will-also-present-a-poster/) - BIOASTER will animate a workshop dedicated to BioTracs-MIMOSA at the RFMF Congress, to present its design and functionalities, and will also present a poster.
- [SFR BIOSCIENCES: 12th annual scientific day](https://www.bioaster.org/sfr-biosciences-12th-annual-scientific-day/) - SFR BIOSCIENCES 12th annual scientific day: "Controlled experimental environments: from cells to ecosystems". Date : Tuesday, June 25th @Domaine St Joseph (Ste Foy-lès-Lyon). Meet Dr. Marion DARNAUD as an invited lecturer about "Gnotobiotics: Innovative & standardized in vivo models to explore microbiome". http://www.bioaster.org/download/sfr-biosciences-program-2019/
- [CLEO/Europe, June 23-27, 2019, Munich, Germany](https://www.bioaster.org/cleo-europe-june-23-27-2019-munich-germany/) - Advanced optics BIOASTER will be attending CLEO/Europe, 23-27 June 2019, Munich, Germany. Dr. Sophie Dixneuf will present The role of bacterial autofluorescence in label-free flow cytometry for fast antibiotic susceptibility testing, results of a research led in the Biological Microsytems & Advanced Optics engineering unit.
- [New collaboration with LNC Therapeutics about Microbiome](https://www.bioaster.org/new-collaboration-with-lnc-therapeutics-about-microbiome/) - BIOASTER announces a collaboration with LNC Therapeutics, a leading biotech in the development of innovative microbiome-based therapies, located in Bordeaux, France. The aim of the partnership is to support LNC Therapeutics’ R&D activities. It will rely on BIOASTER’s expertise and proprietary ANOXIC platform to isolate and cultivate new strains of the strictly anaerobic bacterial species
- [Debiopharm & BIOASTER join forces to expand research to combat infectious diseases.](https://www.bioaster.org/debiopharm-bioaster-join-the-forces-to-expand-research-to-combat-infectious-diseases/) - Debiopharm and BIOASTER announced having officialized a broad research agreement for the development of diagnostic and management innovation for infectious diseases.
- [GNA NOW kicks off its battle against antimicrobial resistance](https://www.bioaster.org/gna-now-kicks-off-its-battle-against-antimicrobial-resistance/) - BIOASTER announces the kick off a new IMI project "GNA NOW" (Gram-Negative Antibacterials NOW), led by Evotec SE, managed by Lygature and funded by the Innovative Medicines Initiative (IMI), a public-private european R&D consortium. The program will work on the development of novel antibacterial agents to battle antimicrobial resistance in gram-negative bacteria. The multi-stakeholder
- [Rapprochement stratégique entre #MétaGénoPolis (MGP) et @BIOASTER : une offre technologique étendue pour l’exploration du #microbiote](https://www.bioaster.org/rapprochement-strategique-entre-metagenopolis-mgp-et-bioaster-une-offre-technologique-etendue-pour-lexploration-du-microbiote/) - Volonté de dynamiser ensemble la recherche autour du microbiote à travers la signature d’un accord afin de proposer une offre de collaboration.
- [Watch our new video about SMART OMICS - Expertises @BIOASTER](https://www.bioaster.org/wathch-our-new-video-about-smart-omics/) - #OmicsTechnologies are today in the heart of early research in #microbiology and #InfectiousDiseases. To leverage these #technologies in applied research, we need to develop new solutions corresponding to industrial processes and needs. In this context, @BIOASTER has developed and implemented the concept of SMART Omics, for the application of #omics technologies in R&D, in our
- [New collaboration with Exeliom Biosciences](https://www.bioaster.org/new-collaboration-with-exeliom-biosciences/) - BIOASTER announces a collaboration with Exeliom Biosciences, a leading biotech in the developement of innovative microbiome-based therapies, located in Paris and Dijon, France. The aim of the partnership is to strengthen Exeliom Biosciences’ production pipeline. It will rely on BIOASTER’s expertise and proprietary ANOXIC platform to measure the viability and cultivability of Extremely Oxygen Sensitive
- [Inscriptions pour le congrès I4ID 2019 toujours ouvertes!](https://www.bioaster.org/registrations-still-open-for-i4id-2019/) - N'oubliez pas de vous inscrire au prochain congrès I4ID 2019! Les inscriptions pour la 3ème édition du programme Immunothérapies et Innovation pour les maladies infectieuses (I4ID2019) sont toujours ouvertes. Le congrès se tiendra les 4 et 5 décembre 2019 à Lyon, en France, et est organisé par MabDesign, BIOASTER et Lyonbiopôle. Pour s'inscrire cliquez ici:
- [Registrations still open for I4ID 2019!](https://www.bioaster.org/registrations-still-open-for-i4id-2019/) - Don't forget to register to the next I4ID 2019 congress! Registration to the 3rd Immunotherapies & Innovation for Infectious Diseases (I4ID2019) that will be held on December 4-5, 2019 in Lyon, France and organized by MabDesign, BIOASTER and Lyonbiopôle. https://i4id.org/register/ The purpose of these two-day congress, jointly organized by @BIOASTER, @MabDesign and @Lyonbiopôle , is
- [Nouvelle collaboration avec Exeliom Biosciences](https://www.bioaster.org/new-collaboration-with-exeliom-biosciences/) - BIOASTER annonce une collaboration avec Exeliom Biosciences, une biotech de premier plan dans le développement de thérapies innovantes liées au microbiome, basée à Paris et à Dijon, France. Ce partenariat vise à renforcer le pipeline de production d’Exeliom Biosciences. Il s’appuiera sur l’expertise de BIOASTER et sur la plateforme ANOXIC brevetée pour mesurer la viabilité
- [A new publication about CHAGAS disease has been released this summer in Metabolomics.](https://www.bioaster.org/a-new-publication-about-chagas-disease-has-been-released-this-summer-in-metabolomics/) - About CHAGAS disease on metabolomics journal. Collaborative with (DNDi) and the London School of Hygiene and Tropical Medicine with BIOASTER OMICS Hub
- [New video on line about BIOFILM: a major issue on public healthcare](https://www.bioaster.org/new-video-on-line-about-biofilm-a-major-issue-on-public-healthcare/) - This video is intended to explain to everyone what the #biofilm is and why it is a key element to improve research, in addition, in the fight against #chronicDiseases and #bacterialResistanceToAntibiotics.With its partners, @BIOASTER develops technologies capable of studying bacteria and their behavior in their natural environment, such as biofilm, and thus actively participates in
- [Meet us at 7th Annual Single Cell Analysis Congress in London, UK](https://www.bioaster.org/meet-us-at-7th-annual-single-cell-analysis-congress-in-london-uk/) - 7th Annual Single Cell Analysis Congress 07 - 08 November 2019, London, UK Microfluidics BIOASTER will be attending the 7th Annual Single Cell Analysis Congress 07 - 08 November 2019, London, UK Dr. Yacine Bounab (Biological systems & Advanced Optics Engineering Unit) will present the droplet microfluidic technology for single cell phenotyping developed at BIOASTER’s
- [BIOASTER obtains certification NGO Source](https://www.bioaster.org/bioaster-obtains-certification-ngo-source/) - BIOASTER, the Technology Research Institute (TRI) gives itself the means to develop new partnerships with American foundations invested in the fight against infectious diseases. The BIOASTER Foundation received an "Equivalency Determination" which allows it to be recognized as a non-profit organization in the United States of America. This equivalence was obtained at the request of
- [Biofilm - Un enjeu majeur de santé publique BIOASTER](https://www.bioaster.org/new-video-on-line-about-biofilm-a-major-issue-on-public-healthcare/) - Le biofilm est un problème majeur de santé publique. Cette vidéo, a pour but d’expliquer à tous ce qu’est le biofilm et pourquoi il est un élément clef pour améliorer les recherches, en autre, dans la lutte contre les maladies chroniques et la résistance bactérienne aux antibiotiques. Avec ses partenaires, BIOASTER développe des technologies capables
- [KICK OFF PROJECT IMI VALUE-DX -European Project](https://www.bioaster.org/kick-off-project-imi-value-dx/) - KICK OFF PROJECT IMI VALUE-DX BIOASTER teams are currently in Madrid for the kick-off meeting of the Value-Dx project. We are proud to be part of such a consortium, funded by the European Union and the Innovative Medicines Initiative, teaming up with industry and academia to fight antimicrobial resistance .
- [BIOASTER et Pherecydes Pharma s'associent pour explorer l'utilisation du traitement par phage pour traiter les infections compliquées des voies urinaires](https://www.bioaster.org/bioaster-and-pherecydes-pharma-join-forces-to-explore-the-use-of-phage-therapy-to-treat-complicated-urinary-tract-infections/) - BIOASTER et Pherecydes Pharma s'associent pour explorer l'utilisation du traitement par phage pour traiter les infections compliquées des voies urinaires
- [New video on line about BIOFILM: a major issue on public healthcare](https://www.bioaster.org/new-video-on-line-about-biofilm-a-major-issue-on-public-healthcare/) - This video is intended to explain to everyone what the #biofilm is and why it is a key element to improve research, in addition, in the fight against #chronicDiseases and #bacterialResistanceToAntibiotics.With its partners, @BIOASTER develops technologies capable of studying bacteria and their behavior in their natural environment, such as biofilm, and thus actively participates in
- [Join us @FLI congress](https://www.bioaster.org/join-us-fli-congress/) - BIOASTER will participate to the next FLI (France Life Imaging) day on September 26th at Orsay. This 5th edition will be dedicated to lastest breakthrough in infectious & inflammation imaging. At this occasion, Dr. Abdessalem REKIKI will give a talk (see program here).
- [SINGLE-MOLECULE SENSORS AND NANOSYSTEMS INTERNATIONAL CONFERENCE – MUNICH; 3-5 APRIL 2019](https://www.bioaster.org/single-molecule-sensors-and-nanosystems-international-conference-munich-3-5-april-2019/) - BIOASTER participated to the Single-Molecule sensors and nanoSystems International Conference which was held in Munich, 3-5 April 2019.
- [Lab-on-a-Chip & Microfluidics Europe 2019 - June, 18-19 in Rotterdam, The Netherlands](https://www.bioaster.org/lab-on-a-chip-microfluidics-europe-2019-june-18-19-in-rotterdam-the-netherlands/) - BIOASTER will be attending Lab-on-a-Chip & Microfluidics Europe 2019, 18-19 June, Rotterdam, The Netherlands.
- [BIOASTER and Pherecydes Pharma join forces to explore the use of phage therapy to treat complicated urinary tract infections](https://www.bioaster.org/bioaster-and-pherecydes-pharma-join-forces-to-explore-the-use-of-phage-therapy-to-treat-complicated-urinary-tract-infections/) - BIOASTER and Pherecydes Pharma join forces to explore the use of phage therapy to treat complicated urinary tract infections
- [Meet us @ASM Microbe 2019- San Francisco, USA](https://www.bioaster.org/meet-us-asm-microbe-2019-san-francisco-usa/) - BIOASTER will participate to the next ASM Microbe meeting from June 20-24 @San Francisco, US. Meet us there! @ASMicrobiology
- [[Workshop - Training] "Introduction to Drug Discovery in a pharma environment" by Gilles Courtemanche](https://www.bioaster.org/workshop-training-introduction-to-drug-discovery-in-a-pharma-environment-by-gilles-courtemanche/) - Workshop Training "Introduction to Drug Discovery in a pharma environment" by Gilles Courtemanche @ Institut Pasteur Paris
- [A DAY@BIOASTER #2 was a great success !](https://www.bioaster.org/a-daybioaster-2-was-a-great-success/) - The second edition of the A Day @ BIOASTER event took place in our offices on April, Thursday 4th, and brought together more than 60 participants and 16 speakers from different “worlds”: academics, industries and SMEs.

## Pages

- [Home](https://www.bioaster.org/) - BIOASTER Technology Research Institute is working to develop an unique technological and innovative model to support the latest challenges in microbiology.
- [La qualité](https://www.bioaster.org/fr/bioaster/la-qualite/) - Home News Press releases Merci Aday Events Merci Aday 2024 Merci A question? Legal notice Mentions légales Home > News Standards industriels et certification ISO La mission de BIOASTER se conçoit uniquement en lien avec ses partenaires, pour accélérer la mise à disposition vers les patients de nouvelles solutions de santé. La satisfaction de nos
- [Rejoignez-nous](https://www.bioaster.org/fr/hr/join-us/) - Home News Press releases Merci Aday Events Merci Aday 2024 Merci A question? Legal notice Mentions légales Home > News A l’image de sa mission, les équipes de BIOASTER sont créatives, multi-disciplinaires, ouvertes et orientées solution. Au-delà des compétences, nous recherchons un état d’esprit, capable de créer des synergies et de relever le défi de
- [Un nouveau modèle de partage des risques de l’innovation](https://www.bioaster.org/fr/bioaster/un-nouveau-modele-de-partage-des-risques-de-linnovation/) - BIOASTER est un IRT en technologies de la santé, créé à l’initiative du Gouvernement français et d’entreprises privées des sciences de la vie.
- [La gouvernance & et le management](https://www.bioaster.org/fr/bioaster/governance-management/) - Home News Press releases Merci Aday Events Merci Aday 2024 Merci A question? Legal notice Mentions légales Home > News La gouvernance Définir une stratégie ambitieuse et assurer sa mise en œuvre La gouvernance de BIOASTER s’appuie sur un Conseil d’Administration et un Comité Stratégique Scientifique. Philippe Archinard – Président Le Conseil d’Administration Les fondateurs
- [Posters & notes d'applications](https://www.bioaster.org/fr/un-projet-avec-bioaster/scientific-communications/posters-application-notes/) - Home > News 2025 xData Unit & Microbiota Program Automatic classification of epithelial tight junctions using graph-extracted metrics BIMOP Unit & xData Unit & Antimicrobial Program RaMoA: Raman micro-spectroscopy and deep learning for rapidly predicting the Mechanism of Action of an antimicrobial and its potential novelty xData Unit & Vaccines Program Comparative analysis of integrative
- [Politique et projets RH](https://www.bioaster.org/fr/hr/politique-rh-et-projets/) - Home News Press releases Merci Aday Events Merci Aday 2024 Merci A question? Legal notice Mentions légales Home > News 1 Maintenir l’équilibre travail/vie personnelle : Organisation Un accord sur le temps de travail (passage à 35 heures avec horaires flexibles et jours fixes) a été signé en 2015, instaurant 12 jours de RTT par
- [Une expérience de travail unique](https://www.bioaster.org/fr/hr/) - Home > News Ressources humaines Une expérience de travail unique Relever le défi de l’innovation technologique au service de la santé ne peut se faire qu’au travers des compétences et de la coopération de personnes engagées. Chez BIOASTER, chaque salarié contribue à son niveau, aux résultats de nos projets collaboratifs, pour faire avancer la recherche.
- [Mentions légales](https://www.bioaster.org/legal-notice/) - Le site https://www.bioaster.org (ci-après le « Site ») que vous consultez actuellement est la propriété de BIOASTER. Les mentions légales qui suivent s’appliquent à tout internaute visitant ce Site.
- [Legal notice](https://www.bioaster.org/legal-notice/) - The www.bioaster.org website (hereinafter the "Site") you are currently visiting is the property of BIOASTER. The following Legal Notice applies to any visitor to this site.
- [Études de cas](https://www.bioaster.org/fr/un-projet-avec-bioaster/study-cases/) - Home > News With more than 400 research contracts and more than 70 collaborative projects, we can report a good number of case studies, in all our fields of application. We have chosen here to present a few cases to you which represent the diversity of the biological questions to which we have answered. Of course, these
- [L’écosystème](https://www.bioaster.org/fr/bioaster/lecosysteme/) - Home News Press releases Merci Aday Events Merci Aday 2024 Merci A question? Legal notice Mentions légales Home > News L’écosystème BIOASTER est acteur ou membre de différents réseaux pour dynamiser l’innovation technologique appliquée & les filières santé. BIOASTER s’inscrit au cœur de l’écosystème santé en France. Ce positionnement permet à l’Institut de faire bénéficier
- [Chikv](https://www.bioaster.org/fr/un-projet-avec-bioaster/study-cases/chikv/) - See all case studies Home > News Development of a rapid diagnostic test supporting drug development in the field of chikungunya infection
- [Covaris](https://www.bioaster.org/fr/un-projet-avec-bioaster/study-cases/covaris/) - See all case studies Home > News A Robust and Standardized Workflow to Analyze C. albicans Differential Protein Expression using Tandem Mass Tag (TMT)
- [Covert](https://www.bioaster.org/fr/un-projet-avec-bioaster/study-cases/covert/) - See all case studies Home > News COVID19 rapid diagnostic tests and humoral response evaluation study
- [Fame](https://www.bioaster.org/fr/un-projet-avec-bioaster/study-cases/fame/) - See all case studies Home > News Fecal Autologous Microbiota Expansion
- [Gna now](https://www.bioaster.org/fr/un-projet-avec-bioaster/study-cases/gna-now/) - See all case studies Home > News Gram-negative antibiotics Now
- [GM15](https://www.bioaster.org/fr/un-projet-avec-bioaster/study-cases/gm15/) - See all case studies Home > News A standardized gnotobiotic mouse model harboring a minimal 15-member mouse gut microbiota recapitulates SOPF/SPF phenotypes
- [HeatStab](https://www.bioaster.org/fr/un-projet-avec-bioaster/study-cases/heatstab/) - See all case studies Home > News Development of an improved protocol for metabolomics analysis, based on heat inactivation of enzymes.
- [InsightCell](https://www.bioaster.org/fr/un-projet-avec-bioaster/study-cases/insightcell/) - See all case studies Home > News Online monitoring of living cells metabolism by nuclear magnetic resonance
- [HoloMoA](https://www.bioaster.org/fr/un-projet-avec-bioaster/study-cases/holomoa/) - See all case studies Home > News Assess the novelty of the mechanism of action of new antimicrobials
- [ATOM](https://www.bioaster.org/fr/un-projet-avec-bioaster/study-cases/atom-2/) - See all case studies Home > News Characterization of the mechanism of action of novel anti-biofilm molecule.
- [xDATA SoftDev](https://www.bioaster.org/fr/un-projet-avec-bioaster/study-cases/xdata-softdev/) - See all case studies Home > News Development of ad-hoc personalized sotware to allow big-data cross- referencing from different sources
- [Metagenomics](https://www.bioaster.org/fr/un-projet-avec-bioaster/study-cases/metagenomics/) - See all case studies Home > News Develop a ready-to-use and robust toolbox for Metagenomic applications and evaluate microbiome-based biomarkers of added medical value
- [Mosaic](https://www.bioaster.org/fr/un-projet-avec-bioaster/study-cases/mosaic/) - See all case studies Home > News Studying molecular signatures of adjuvanted vaccine candidates through translational approaches Risk mitigation
- [Multiway](https://www.bioaster.org/fr/un-projet-avec-bioaster/study-cases/multiway/) - See all case studies Home > News Development of a new multiplex technology adapted to Point of Care diagnosis
- [Prochick](https://www.bioaster.org/fr/un-projet-avec-bioaster/study-cases/prochick/) - See all case studies Home > News Establishment of a collection of commensal bacterial strains of chicken for exploration as potential probiotic candidates
- [Onchocerco](https://www.bioaster.org/fr/un-projet-avec-bioaster/study-cases/onchocerco/) - See all case studies Home > News Development of a lateral flow assay for Onchocerciasis detection
- [Ysopia](https://www.bioaster.org/fr/un-projet-avec-bioaster/study-cases/ysopia/) - See all case studies Home > News Targeted enrichment and culture
- [CODIRA](https://www.bioaster.org/fr/un-projet-avec-bioaster/study-cases/codira/) - See all case studies Home > News Advanced optics for rapid bacteria detection and Antibiotic Susceptibility Testing (AST) AST: Antibiotic Susceptibility Testing ID: IDentification – TTR: Time-To-Result
- [AllTest](https://www.bioaster.org/fr/un-projet-avec-bioaster/study-cases/alltest/) - See all case studies Home > News Lateral flow antigenic rapid IVD assessment
- [ISYBIO](https://www.bioaster.org/fr/un-projet-avec-bioaster/study-cases/isybio/) - See all case studies Home > News Comparative analysis of supervised integrative methods for multi-omics data
- [Isit-tb](https://www.bioaster.org/fr/un-projet-avec-bioaster/study-cases/isit-tb/) - See all case studies Home > News Detect active TB cases, diagnose & monitor treatment of patients using blood based-RNA biomarkers
- [Un projet avec BIOASTER](https://www.bioaster.org/fr/un-projet-avec-bioaster/) - Home > News Introduction Que pouvez-vous attendre de BIOASTER? Nous vous aidons à définir et/ou à mettre en œuvre les technologies dont vous avez besoin pour développer vos solutions prophylactiques, diagnostiques et thérapeutiques en microbiologie et maladies infectieuses. Chez BIOASTER nous sommes conscient qu’identifier, sélectionner et accéder à des technologies spécialisées, et à des experts
- [Portail de transparence](https://www.bioaster.org/fr/un-projet-avec-bioaster/portail-de-transparence/) - Home > News Bienvenue sur le portail de transparence de BIOASTER. Comme cela a pu vous être indiqué, il vous permet de prendre connaissance des études cliniques promues par BIOASTER, notamment celles qui utilisent des informations recueillies au cours de votre prise en charge et des soins qui vous sont apportés. Pour votre information, certaines
- [Grants & projets Européens](https://www.bioaster.org/fr/un-projet-avec-bioaster/grants-eu-projects/) - Home > News Projets européens, grants et financements non dilutifs En notre qualité d’Institut de Recherche Technologique et avec pour mission de traduire une recherche académique en solution industrielle, nous sommes convaincus que nous devons nous fédérer, acteurs privés et académiques pour bâtir des projets de R&D dimensionnant, au niveau local, national, européen et international.
- [Accueil](https://www.bioaster.org/) - Favoriser, accélérer et apporter une nouvelle valeur ajoutée aux projets collaboratifs pour mieux répondre aux enjeux de santé globale.
- [Communiqué de presse](https://www.bioaster.org/news/press-releases/) - Consultez tous nos derniers communiqués de presse et contacts presse concernant notre institut d'innovation technologique en microbiologie appliquée.
- [La RSE](https://www.bioaster.org/fr/bioaster/la-rse/) - Home News Press releases Merci Aday Events Merci Aday 2024 Merci A question? Legal notice Mentions légales Home > News La responsabilité sociétale entreprise BIOASTER prône et défend une démarche : RSE volontariste et évolutive pour favoriser toutes les initiatives et les actions qui renforcent son impact positif vers les patients, les collaborateurs, les partenaires
- [CSS](https://www.bioaster.org/fr/bioaster/css/) - Home News Press releases Merci Aday Events Merci Aday 2024 Merci A question? Legal notice Mentions légales Home > News Le Comité de Stratégie Scientifique se réunit 2 fois par an dans les locaux de BIOASTER. Le Comité de stratégie scientifique rassemble des chercheuses et chercheurs reconnus à l’international, issus de divers champs disciplinaires en
- [Evénements](https://www.bioaster.org/news/events/) - Retrouvez tous nos derniers communiqués de presse et contact presse sur notre institut d'innovation technologique en microbiologie appliquée.
- [Events](https://www.bioaster.org/news/events/) - See all our latest press releases and press contact about our institute for technological innovation in applied microbiology.
- [Microbiote](https://www.bioaster.org/fr/fields-of-applications/microbiota/) - Home > News Au cours des deux dernières décennies, les nouvelles technologies ont permis aux chercheurs d’évaluer la composition des microbiomes et leurs rôles potentiels. Ainsi, les technologies modernes ont vu le jour ouvrant à une nouvelle ère d’opportunités pour l’exploitation du microbiote comme nouvelle source de solutions diagnostiques, prophylactiques ou thérapeutiques. Alors que vous
- [Diagnostic & Diagnostic Compagnon](https://www.bioaster.org/fr/fields-of-applications/diagnostic/) - Home > News Nous identifions et validons des biomarqueurs ayant une valeur médicale ajoutée et des technologies innovantes permettant un diagnostic plus rapide et précis en soutien du développement de médicaments. Au cours des 20 dernières années, de nouvelles technologies d’identification des agents pathogènes, telles que le séquençage de nouvelle génération, les panels moléculaires multiplex, ainsi
- [Data Science, Gestion des données et Solutions Digitales](https://www.bioaster.org/fr/innovation-solutions-technologiques/plateformes-technos/data/) - Home > News SCIENCE DES DONNEES, GESTION DE DONNEES ET SOLUTIONS NUMERIQUES Apporter le continuum de technologies numériques et de science des données essentiel à l’atteinte des objectifs d’analyse avancée de données de votre projet. La masse de données générées par les expériences à haut ou moyen débit, le NGS, les analyses multi-omiques et l’imagerie
- [Vaccins](https://www.bioaster.org/fr/fields-of-applications/vaccines/) - Home > News Bien que les vaccins aient considérablement réduit la mortalité et la morbidité de nombreuses maladies, ils ont pour la plupart été développés de manière empirique. Il reste donc des défis importants à relever dans le développement de nouveaux vaccins, comme l’a confirmé la récente pandémie de SARS-CoV-2. Au cours des deux dernières
- [Antimicrobiens](https://www.bioaster.org/fr/fields-of-applications/antimicrobials/) - Home > News Notre mission est de développer des connaissances, des savoir-faire et des technologies pour connaitre, comprendre et analyser les interactions entre hôte/pathogène/solution thérapeutique et contribuer ainsi à lutter contre l’émergence de nouvelles pathologies infectieuses et la résistance aux antimicrobiens (ou AMR en anglais). En qualité de développeur des solutions thérapeutiques curatives ou préventives,
- [Opérations Cliniques](https://www.bioaster.org/fr/innovation-solutions-technologiques/plateformes-technos/cliop/) - Home > News Opérations Cliniques Notre objectif est de vous donner accès à des échantillons biologiques humains bien caractérisés, qualitatifs et adaptés à vos besoins pour accélérer vos projets de développement de produits de santé. L’accès à des échantillons bien caractérisés et documentés favorise grandement le développement de produits de santé innovants. Les défis souvent
- [Merci Aday 2024](https://www.bioaster.org/news/merci-aday-2024/) - Home > News Aday@BIOASTER: The race against Antimicobial Resistance! Merci d’avoir participé à l’évènement Aday@BIOASTER: The race against Antimicrobial Resistance! Thank you for your participation to our event Aday@BIOASTER: The race against Antimicrobial Resistance! You will find below the program, some speaker’s presentations (Work in Progress) and some pictures of the event. SPEAKERS: Khaled ABOUSALEH,
- [Publications](https://www.bioaster.org/fr/un-projet-avec-bioaster/scientific-communications/publications/) - Home > News Identification and antifungal susceptibility patterns of reference yeast strains to novel and conventional agents: a comparative study using CLSI, EUCAST and Sensititre YeastOne methods Andres Ceballos-Garzon, Marion Holzapfel, Jeremy Welsch, Derry Mercer Targeting the early life stages of SARS-CoV-2 using a multi-peptide conjugate vaccine Lauren Myburgh 1, Haiko Karsjens 1, Athanasios Blanas 1, Aafke de Ligt 1, Karlijn van Loon 1, Elisabeth J M Huijbers 2, Judy
- [Bioessais, Microsystèmes et Ingénierie Optique](https://www.bioaster.org/fr/innovation-solutions-technologiques/plateformes-technos/bimop/) - Home > News Bioessais, Microsystèmes et Ingénierie Optique Nous vous fournissons des technologies bioanalytiques innovantes pour les maladies infectieuses et le microbiote. Les outils bioanalytiques conçus et personnalisés sont importants pour déchiffrer, détecter et caractériser les agents pathogènes des maladies infectieuses, évaluer les vaccins et les thérapies contre les agents pathogènes, et pour la réponse
- [Microbiologie et Ingénierie Moléculaire](https://www.bioaster.org/fr/innovation-solutions-technologiques/plateformes-technos/micro/) - Home > News Concevoir et développer des solutions scientifiques et technologiques originales pour accélérer la recherche microbiologique au profit de la santé animale et humaine. Notre mission est de concevoir et développer des solutions scientifiques et technologiques originales pour accélérer la recherche microbiologique au bénéfice de la santé animale et humaine. Nous apportons une expertise
- [Modèles Précliniques et Imagerie](https://www.bioaster.org/fr/innovation-solutions-technologiques/plateformes-technos/premi/) - Home > News Modèles Précliniques et Imagerie Nous développons pour vous des modèles animaux/technologies innovants pour l’étude des maladies infectieuses et du microbiote. Les modèles animaux représentent des outils précieux pour l’étude des maladies infectieuses et l’évaluation des interactions hôte/pathogène. Ces modèles animaux facilitent l’évaluation préclinique, par exemple, des vaccins ou des thérapies innovantes pour
- [Références](https://www.bioaster.org/fr/un-projet-avec-bioaster/references/) - Home > News Non clinical reproductive and developmental safety evaluation of he MAGE-A3 Cancer Immunotherapeutic, a therapeutic vaccine for cancer treatment Our project partners Here is a short list of partners, academic or industrial, with whom we have carried out collaborative projects. We are proud of the diversity of entities that have trusted us to
- [Convictions, missions, valeurs](https://www.bioaster.org/fr/bioaster/convictions-missions-values/) - Home > News Non clinical reproductive and developmental safety evaluation of he MAGE-A3 Cancer Immunotherapeutic, a therapeutic vaccine for cancer treatment Notre raison d’être : l’innovation technologique NOS CONVICTIONS Les maladies d’origine microbienne sont et resteront une menace de santé publique. Elles ont des causes multiples comme par exemple les maladies émergentes, l’AMR, et la
- [COVID-AuRA Translate](https://www.bioaster.org/fr/un-projet-avec-bioaster/covid-aura/) - Home > News Non clinical reproductive and developmental safety evaluation of he MAGE-A3 Cancer Immunotherapeutic, a therapeutic vaccine for cancer treatment An accelerator for developing new diagnostic, prognostic and treatment solutions against SARS-CoV-2 infections, leveraging understanding of host response mechanisms. A Unique Public-Private Multidisciplinary Consortium Federating Global Pharmaceutical Companies, Local University Hospitals and Research Centers,
- [Merci Aday](https://www.bioaster.org/news/merci-aday/) - Home > News Aday@BIOASTER: The future of vaccines ! Merci d’avoir participé à l’évènement Aday@BIOASTER: The future of vaccines ! Thank you for your participation to our event Aday@BIOASTER: The future of Vaccines! You will find below the program, some speaker’s presentations and even some pictures of the event. SPEAKERS: Dr. Xavier MORGE, PharmaD –
- [Press releases](https://www.bioaster.org/news/press-releases/) - See all our latest press releases and press contact about our institute for technological innovation in applied microbiology.
- [Vos contacts](https://www.bioaster.org/fr/un-projet-avec-bioaster/your-contacts/) - Une question pour notre département des ressources humaines ? Pour postuler ou envoyer votre CV, veuillez vous rendre sur la page dédiée aux RH sur le site web ici. hr@bioaster.org Vous avez une question concernant un sujet scientifique ou technologique ? Choisissez entre : diagnostic@bioaster.org vaccines@bioaster.org antimicrobials@bioaster.org microbiota@bioaster.org technology@bioaster.org Vous êtes journaliste ou vous avez
- [A question?](https://www.bioaster.org/contacts/) - BIOASTER - Headquarters : 40 avenue Tony Garnier, 69007 Lyon (France). BIOASTER - Paris : Bâtiment F. Jacob, 28 rue du docteur Roux, 75015 Paris (France)
- [Une question ?](https://www.bioaster.org/contacts/) - BIOASTER - Siège social : 40 avenue Tony Garnier, 69007 Lyon. BIOASTER - Paris : Bâtiment F. Jacob, 28 rue du docteur Roux, 75015 Paris
- [OMICS](https://www.bioaster.org/fr/innovation-solutions-technologiques/plateformes-technos/omics/) - Home > News OMICS Nous proposons des innovations dans le domaine des Omiques afin de surmonter les obstacles technologiques. Les technologies Omiques, intégrées dans une approche de biologie des systèmes, sont désormais au cœur de la recherche en microbiologie et maladies infectieuses. Cependant, pour faire partie intégrante de la chaîne de valeur industrielle, les solutions
- [Technologies](https://www.bioaster.org/fr/innovation-solutions-technologiques/plateformes-technos/) - Home > News Non clinical reproductive and developmental safety evaluation of he MAGE-A3 Cancer Immunotherapeutic, a therapeutic vaccine for cancer treatment BIOASTER aide ses partenaires industriels à faire face aux points critiques et à relever les défis technologiques. Depuis sa création en 2012, BIOASTER, en tant qu’institut de technologie de recherche, investit continuellement dans des
- [Futur talent](https://www.bioaster.org/fr/lets-be-spontaneous/) - Rejoignez notre vivier de talent! Formulaire de candidature spontanée! Si aucuns des postes disponibles ne vous convient, n’hésitez pas à nous envoyer votre candidature spontanée en remplissant le formulaire ci-dessous:
- [Nos domaines d'interventions](https://www.bioaster.org/fr/fields-of-applications/) - Home > News Non clinical reproductive and developmental safety evaluation of he MAGE-A3 Cancer Immunotherapeutic, a therapeutic vaccine for cancer treatment LES QUATRE DOMAINES DE LA MICROBIOLOGIE ET DES MALADIES INFECTIEUSES POUR LES APPLICATIONS EN R&D NOUS AVONS POUR OBJECTIF DE VOUS FOURNIR DES SOLUTIONS SCIENTIFIQUES, TECHNOLOGIQUES ET FINANCIÈRES INNOVANTES POUR ACCÉLÉRER LE DÉVELOPPEMENT DE
- [Nos métiers](https://www.bioaster.org/fr/hr/nos-metiers/) - Home > News Non clinical reproductive and developmental safety evaluation of he MAGE-A3 Cancer Immunotherapeutic, a therapeutic vaccine for cancer treatment Dr Constance EnriquezResponsable des Affaires Européennes et Internationales/ Grant Office “A BIOASTER j’ai pu développer de nouvelles interactions avec des nouveaux acteurs du secteur que je ne connaissais pas. Cela m’a permis d’élargir mon
- [Travailler ensemble](https://www.bioaster.org/fr/hr/vivre-ensemble/) - Home > News Non clinical reproductive and developmental safety evaluation of he MAGE-A3 Cancer Immunotherapeutic, a therapeutic vaccine for cancer treatment Une aventure humaine En avril 2012, à l’initiative du gouvernement français, l’Institut Pasteur et Lyonbiopole décident de développer un modèle unique et innovant pour répondre aux enjeux technologiques dans l’infectiologie et la microbiologie. Une
- [Data](https://www.bioaster.org/fr/our-offers/data/) - Home > News Non clinical reproductive and developmental safety evaluation of he MAGE-A3 Cancer Immunotherapeutic, a therapeutic vaccine for cancer treatment Relever les défis des sciences de la vie en matière de données Maîtriser l’ensemble de la chaîne de valeur des données pour servir les enjeux d’intégration et d’analyse avancées des données des projets des
- [Biomarqueurs](https://www.bioaster.org/fr/our-offers/biomarkers/) - Home > News Non clinical reproductive and developmental safety evaluation of he MAGE-A3 Cancer Immunotherapeutic, a therapeutic vaccine for cancer treatment Biomarqueurs Dans le domaine des biomarqueurs, notre valeur ajoutée repose sur : l’intégration de l’expertise en matière de biomarqueurs depuis la phase de découverte jusqu’à la phase de développement, la collaboration avec des cliniciens
- [Modèles in vitro/in vivo](https://www.bioaster.org/fr/our-offers/in-vitro-in-vivo-models/) - Home > News Modèles in vitro/in vivo De l’ingénierie de modèles in vitro pertinents aux modèles validés in vivo : réduire les risques et accélérer le développement de vos produits Criblage in vitro de candidats médicaments pour leurs activités anti-infectieuses ou probiotiques : études in vitro utilisant des approches microbiologiques standard, systèmes cellulaires in vitro
- [Mécanisme d'action - Réponse de l'hôte, activité et efficacité de vos antimicrobiens](https://www.bioaster.org/fr/our-offers/mecanisms-of-action-therapeutic-solutions/) - Home > News Non clinical reproductive and developmental safety evaluation of he MAGE-A3 Cancer Immunotherapeutic, a therapeutic vaccine for cancer treatment Évaluez le mécanisme d’action, la réponse de l’hôte, l’activité, le profilage et l’efficacité de vos antimicrobiens pour alimenter un pipeline de nouveaux médicaments au bénéfice des patients. Le besoin de nouveaux agents présentant une
- [Mécanisme d'action - Solutions Prophylactiques](https://www.bioaster.org/fr/our-offers/mecanisms-of-action-prophylactic-solutions/) - Home > News Non clinical reproductive and developmental safety evaluation of he MAGE-A3 Cancer Immunotherapeutic, a therapeutic vaccine for cancer treatment Déchiffrer le mécanisme d’action déclenché par vos solutions prophylactiques Dans le contexte du développement de vaccins, la caractérisation du mécanisme d’action de votre candidat vaccin est un atout essentiel lors de la soumission aux
- [Développements technologiques](https://www.bioaster.org/fr/our-offers/life-science-technology-development/) - Home > News Non clinical reproductive and developmental safety evaluation of he MAGE-A3 Cancer Immunotherapeutic, a therapeutic vaccine for cancer treatment Technological developments Le développement de solutions de santé plus ciblées, efficaces et personnalisées implique que la technologie fasse désormais partie intégrante d’un programme de R&D. En tant que société de développement de produits de
- [Micro-organismes - Echantillons d'intérêt](https://www.bioaster.org/fr/our-offers/samples-of-interest/) - Home > News Non clinical reproductive and developmental safety evaluation of he MAGE-A3 Cancer Immunotherapeutic, a therapeutic vaccine for cancer treatment Accès à des échantillons biologiques bien caractérisés et documentés pour explorer les interactions hôte-pathogène Notre objectif est de fournir des micro-organismes, des échantillons précliniques et cliniques caractérisés et documentés pour soutenir vos recherches en
- [Nos offres](https://www.bioaster.org/fr/our-offers/) - Home > News Introduction Comment contribuons-nous à lever les barrières technologiques dans les phases critiques de vos développements ? Nous déployons ou développons une expertise adaptée en exploitant nos solutions technologiques applicables aux domaines de la microbiologie et des maladies infectieuses. Notre objectif est de vous permettre de rendre possible ou d’accélérer le développement de
- [Vidéos](https://www.bioaster.org/fr/un-projet-avec-bioaster/scientific-communications/videos/) - Home > News Non clinical reproductive and developmental safety evaluation of he MAGE-A3 Cancer Immunotherapeutic, a therapeutic vaccine for cancer treatment Covid AuRA JT France 3 19 20 21 05 2021 SMART OMICS 2021 / EXPERTISES AT BIOASTER H264 1080P STUK LUMI-Seq®: TECHNOLOGIES DESIGNED BY BIOASTER, H264 2020 STUK BIOASTER BIOFILM: major issue on public
- [Communications Scientifiques](https://www.bioaster.org/fr/un-projet-avec-bioaster/scientific-communications/) - Home > News Non clinical reproductive and developmental safety evaluation of he MAGE-A3 Cancer Immunotherapeutic, a therapeutic vaccine for cancer treatment Publications, posters et vidéos Vous trouverez dans cette rubrique une sélection de nos publications, nos posters et quelques vidéos pour illustrer notre savoir-faire particulier. Bien entendu, nous sommes à votre disposition pour discuter de
- [Merci](https://www.bioaster.org/news/merci/) - Home > News Merci d’avoir célébré nos 10 ans avec nous ! « BIOASTER, c’est l’innovation et le décloisonnement et, à chaque fois que l’on décloisonne, on fait bouger les lignes et on gagne ! » Alain Mérieux Interventions M. Philippe Archinard, Président de BIOASTER M. Alain Mérieux, Président de l’Institut Mérieux et 1er Président
- [Merci](https://www.bioaster.org/news/merci/) - Home > News Merci d’avoir célébré nos 10 ans avec nous ! Nullam quis risus eget urna mollis ornare vel eu leo. Curabitur blandit tempus porttitor. Cras justo odio, dapibus ac facilisis in, egestas eget quam. Nullam id dolor id nibh ultricies vehicula ut id elit. Cras justo odio, dapibus ac facilisis in, egestas eget
- [Mentions légales](https://www.bioaster.org/mentions-legales/) - The http://www.bioaster.org site (hereinafter the "Site") that you are currently viewing is the property of BIOASTER.
- [BIOASTER](https://www.bioaster.org/fr/bioaster/) - Home > News Non clinical reproductive and developmental safety evaluation of he MAGE-A3 Cancer Immunotherapeutic, a therapeutic vaccine for cancer treatment
- [Communiqués](https://www.bioaster.org/fr/actualites/communiques/) - En attente de contenu
- [News](https://www.bioaster.org/news/) - En attente de contenu
- [Actualités](https://www.bioaster.org/fr/actualites/) - En attente de contenu
- [Innovation & solutions technologiques](https://www.bioaster.org/fr/innovation-solutions-technologiques/) - Home > News Introduction Duis mollis, est non commodo luctus, nisi erat porttitor ligula, eget lacinia odio sem nec elit. Donec sed odio dui. Fusce dapibus, tellus ac cursus commodo, tortor mauris condimentum nibh, ut fermentum massa justo sit amet risus. Vivamus sagittis lacus vel augue laoreet rutrum faucibus dolor auctor. Maecenas sed diam eget
- [Actualités, événements, publications de presse](https://www.bioaster.org/fr/actualites-evenements-publications-de-presse/) - Partagez en ligne nos actualités, événements, publications de presse de notre institut d’innovation technologique en microbiologie.

## Events

- [Join us @World Vaccine congress Europe, Barcelona, Spain](https://www.bioaster.org/event/join-us-world-vaccine-congress-barcelona-spain/) - Join us @World Vaccine congress Europe, Barcelona, Spain from october 11th to 14th, 2022!! BIOASTER will attend The World Vaccine Congress 2022 tomorrow!! Looking for us? Table top N°3 close to the poster zone from October 11th to 14th, 2022 at Bacelona, Spain. More info: HERE #vaccines #Vaccinenetwork #Vaccinecongress
- [BIOASTER is a proud participant to the next edition of I4ID 2022](https://www.bioaster.org/event/i4id-2022-immunotherapies-innovations-for-infectious-diseases/) - BIOASTER will actively participate to the next edition of I4ID 2022, the Immunotherapies & Innovations for Infectious Diseases congress that will take place on november 23th to 24th @Ens-Lyon, France. Meet BIOASTER team there at our exhibition's desk. More info soon. More information about the congress: program, speakers...? Have a look to the I4ID website.
- [Lancement du projet NextGenBioProcess, lauréat de l’appel à projet R&D Booster](https://www.bioaster.org/event/lancement-du-projet-nextgenbioprocess-laureat-de-lappel-a-projet-rd-booster/) - Coordonné par GENCOVERY et en partenariat avec GREENCELL et l’IRT BIOASTER, le projet NextGenBioProcess, lauréat de l’appel à projets R&D Booster de la Région Auvergne-Rhône-Alpes, a démarré le 12 octobre 2022 lors d’une réunion de lancement entre les partenaires et avec la participation de Aurore Niemec (Région Auvergne-Rhône-Alpes) au sein des locaux de Pulsalys. Télécharger
- [BIOASTER gives a talk @ "Emerging technologies in #probiotic , live #biotherapeutics product and #microbiome analysis" virtual symposium](https://www.bioaster.org/event/bioaster-emerging-technologies-in-probiotic-live-biotherapeutics-product-and-microbiome-analysis-virtual-symposium/) - BIOASTER participate to the "Emerging technologies in #probiotic , live #biotherapeutics product and #microbiome analysis" virtual symposium organised by US Pharmacopeia on October 6th to 7th. Connect to attend the talk of Vincent Thomas, our head of #microbiome Program on Friday October 7th about " Rapid Monitoring of #microbiota Composition and #TargetedCulturomics of Species of Interest using #Polyclonal #antibodies in combination with #flowcytometry "! See you there! More information here
- [Pherecydes Pharma and BIOASTER join forces in the treatment of bacteremia](https://www.bioaster.org/event/pherecydes-pharma-and-bioaster-join-forces-in-the-treatment-of-bacteremia/) - “BIOASTER is thrilled to bring its expertise, its resources and its technology innovations to contribute to the success of a challenging and promising research program of Pherecydes, a Pharma French biotech. Through this program, we are proud to join the fight against antimicrobial resistance though the use of phages.” Dr. Nathalie GARCON, CSO BIOASTER Download
- [BIOASTER partenaire de la Journée collaborative de Lyonbiopole](https://www.bioaster.org/event/bioaster-partenaire-de-la-journee-collaborative-de-lyonbiopole/) - Comme chaque année, BIOASTER est partenaire de la Journée Collaborative organisée par Lyonbiopole le 14/10 au WTC de Grenoble. 🚨 Participez à la table ronde N°5, co-organisée avec BIOASTER: - Vaccin : Promesses et perspectives des nouvelles plateformes vaccinales multimériques! INSCRIVEZ -vous ici: Journée Collaborative par Lyonbiopôle PRESENTATION DE LA JOURNEE COLLABORATIVE Inscrivez-vous à la
- [1st Edition of Pasteur Innov'day 2022](https://www.bioaster.org/event/1st-edition-of-pasteur-innovday-2022/) - On July 7th, BIOASTER participated to the 1st edition of the Pasteur Innov'day organized by Institut Pasteur! Many thanks to all visitors who came to see our stand! Many thanks to our BIOASTER team on site! #innovation #healthcareinnovation
- [IABS meeting BIOASTER FMT Webinar](https://www.bioaster.org/event/iabs-meeting-bioaster-fmt-webinar/) - Join the 2nd IABS webinar on Standards for Faecal Microbiota Transplant: Tools and Therapeutic Advances ! Organized by BIOASTER on May 24th & May 25th from 16:00 to 18:30 CEST // 10:00 am - 12:30 pm EDT Click for the Flyer: IABS-BIOASTER_2nd FMT Webinar_May 24 + May 25 2022 Abstract: Faecal microbiota transplantation (FMT) is
- [Webinar SFM](https://www.bioaster.org/event/webinar-sfm/)
- [IRCI Symposium on Immune Response in Cancer and Infection @TBD, Lyon, FR](https://www.bioaster.org/event/irci-symposium-on-immune-response-in-cancer-and-infection-tbd-lyon-fr/) - IRCI Symposium on Immune Response in Cancer and Infection organized by CLARA (AuRA) Canceropole Auvergne Rhone Alpes. Stand organised by Microbiota program.
- [IPA World Congress & PROBIOTA Americas @Washington DC, US](https://www.bioaster.org/event/ipa-world-congress-probiota-americas-washington-dc-us/) - IPA World Congress + Probiota Americas @Washington DC, USA Talk of Vincent Thomas, head of Microbiota program The IPA World Congress + Probiota Americas 2020 brings together global experts to share insights on scientific and market aspects of the synbiotic field. Probiota Americas is the leading annual event for the prebiotic, probiotic and the microbiota-focused food and pharma industries in the
- [Congress ECCMID 2022 – April 23-26 @Lisbon, Portugal](https://www.bioaster.org/event/congres-eccmid-2022-april-23-26-lisbon-portugal/) - Congress ECCMID 2022 – hybrid format @ Lisbonne, Portugal B2B with Diagnostic program member
- [Probiota Global 2022 @Copenhagen, Denmark](https://www.bioaster.org/event/probiota-global-2022-copenhagen-denmark/) - Congres Probiota Global 2022@Copenhagen, Denmark Connecting the business and science of the microbiome. Participation of Vincent THOMAS, head of Microbiota program.
- [Microbiome R&D & Business Collaboration Forum: Europe @La Haye, NL](https://www.bioaster.org/event/microbiome-rd-business-collaboration-forum-europe-la-haye-nl/) - Microbiome R&D & Business Collaboration Forum: Europe @La Haye, NL https://www.global-engage.com/event/microbiota/ Particpation of Microbiota program Head of Partnership developpement: Nadège ADOUARD
- [Congress Biosensor meeting](https://www.bioaster.org/event/congress-biosensor-meeting/) - 16th International Conference & Exhibition on Biosensors & Bioelectronics May 27-28, 2022 Montreal, Canada Innovations & Reforms in the field of Biosensors Team Diagnostic Program
- [Congress Pharmabiotics Conference @Lyon, FR](https://www.bioaster.org/event/congress-pharmabiotics-conference-lyon-fr/) - Congress Pharmabiotics Conference @Lyon, FR https://www.pharmabioticsevent.com/ Participation of all Microbiota program team: Talk of Dr. Vincent THOMAS Stand of Nadège ADOUARD Poster about Gut on chip from Ilia BELOTSERKOVSKY
- [Symposium EMBL, Heidleberg, 06-09 Avril](https://www.bioaster.org/event/symposium-embl-heidleberg-06-09-avril/) - Symposium EMBL, Heidleberg, Germany Participation Microbiota program member: Nadège ADOUARD
- [Cell Factories for Industrial Bioproduction (CFIB)](https://www.bioaster.org/event/cell-factories-for-industrial-bioproduction-cfib/) - Congress Cell Factories for Industrial Bioproduction (CFIB) in Biocitech Technology Park Paris-Romainville Registration & information: https://asso.adebiotech.org/colloques/cell-factories-for-industrial-bioproduction/ Participation of Nadège Adouard from Microbiota program. https://asso.adebiotech.org/wp-content/uploads/2022/02/CFIB2022_Flyer-1.pdf
- [New Publication on "Evolution of FMT - From early clinical to standardized treatments" has been published on BIOASTER](https://www.bioaster.org/event/new-publication-on-evolution-of-fmt-from-early-clinical-to-standardized-treatments-has-been-published-on-bioaster/) - New Publication on "Evolution of FMT - From early clinical to standardized treatments" has been published on BIOASTER-
- [MEET AT THE 5TH MICROBIOTA & HEALTH DAY ORGANIZED BY LYONBIOPOLE](https://www.bioaster.org/event/meet-at-the-5th-microbiota-health-day-organized-by-lyonbiopole/) - See you at the 5th Microbiota & Health day organized by LyonBioPole on February 3, 2022 in person at the Cité Internationale de la Gastronomie in Lyon (2nd). Come and meet our Microbiota program team (Vincent Thomas, program manager and Nadège Adouard our strategic partnerships manager). Vincent Thomas will present on “New tools for the
- [AMR Mission Sweden 2022 online - B2B](https://www.bioaster.org/event/amr-mission-sweden-2022-online-b2b/) - AMR Mission Sweden 2022 – online - B2B Diagnostic Programm will be there.
- [International conference HUB VPH : Human - Animal One Health:  At the Confluence of human & veterinary public health](https://www.bioaster.org/event/international-conference-hub-vph-human-animal-one-health-at-the-confluence-of-human-veterinary-public-health/)
- [MICROBES 2021: Next SFM (the French Society of Microbiology) congress](https://www.bioaster.org/event/microbes-2021-prochain-congres-de-la-sfm/) - MICROBES 2021: a thousand places at the heart of microbiology. The next and 16th congress of The French Society of Microbiology (SFM) will take place on september, from 22th to the 24th, 2021 at the congress center of Nantes (Cité des congrès de NANTES). On this occasion, do not miss the presentation of Dr Vincent
- [MICROBES 2021: Prochain congrès de la SFM](https://www.bioaster.org/event/microbes-2021-prochain-congres-de-la-sfm/) - MICROBES 2021: mille lieux au coeur de la microbiologie. Prochain et 16ème congrès de la SFM (Société Française de Microbiologie) se tiendra du 22 au 24 septembre 2021 à la Cité des congrès de NANTES. A cette occasion, ne manquez pas la présentation de Vincent Thomas (responsable programme Microbiote à BIOASTER) sur "Suivi rapide de
- [BIOASTER exclusively licenses blood-based biomarkers for Tuberculosis diagnosis](https://www.bioaster.org/event/bioaster-exclusively-licenses-blood-based-biomarkers-for-tuberculosis-diagnosis/) - An international public-private collaborative study coordinated by BIOASTER has highlighted the value of blood-based transcriptomic biomarkers to improve early Tuberculosis (TB) diagnosis.
- [BIOASTER signe un contrat de licence exclusive sur des biomarqueurs sanguins pour le diagnostic de la tuberculose](https://www.bioaster.org/event/bioaster-exclusively-licenses-blood-based-biomarkers-for-tuberculosis-diagnosis/) - Une étude collaborative internationale coordonnée par BIOASTER a démontré la valeur des biomarqueurs transcriptomiques sanguins pour améliorer le diagnostic précoce de la tuberculose.
- [BIOASTER et Evotec collaborent au développement d’un test de diagnostic rapide](https://www.bioaster.org/event/bioaster-collaborates-with-evotec-to-develop-a-rapid-diagnostic-test-supporting-drug-development-in-the-field-of-chikungunya-infection/) - BIOASTER et Evotec collaborent au développement d’un test de diagnostic rapide en lien avec l’évaluation d’une nouvelle molécule thérapeutique dans le domaine de l’infection par le virus Chikungunya
- [BIOASTER collaborates with Evotec to develop a rapid diagnostic test supporting drug development in the field of chikungunya infection](https://www.bioaster.org/event/bioaster-collaborates-with-evotec-to-develop-a-rapid-diagnostic-test-supporting-drug-development-in-the-field-of-chikungunya-infection/) - BIOASTER, the French Technology Research Institute for Microbiology and Infectious Diseases, has today announced a new collaboration with Evotec in the field of chikungunya infection diagnosis.
- [A la recherche de solutions pour contourner les écueils du développement de nouveaux antibiotiques, dans un système économique difficile.](https://www.bioaster.org/fr/event/a-la-recherche-de-solutions-pour-contourner-les-ecueils-du-developpement-de-nouveaux-antibiotiques-dans-un-systeme-economique-difficile/) - Une revue d’opinion des ambassadeurs du réseau international AMR Insight avec le Dr Gilles Courtemanche, Associate Director, Antimicrobials Unit @bioaster...
- [Looking for Solutions to the Pitfalls of Developing Novel Antibacterials in an Economically Challenging System](https://www.bioaster.org/event/looking-for-solutions-to-the-pitfalls-of-developing-novel-antibacterials-in-an-economically-challenging-system/) - An opinion review from AMR Insight ambassadors with Dr Gilles Courtemanche, Associate Director, Antimicrobials Unit @bioaster Authors: Gilles Courtemanche, Rohini Wadanamby, Amritanjali Kiran, Luisa Fernanda Toro-Alzate, Mathew Diggle, Dipanjan Chakraborty, Ariel Blocker and Maarten van Dongen Reference: Microbiol. Res. 2021, 12(1), 173-185; https://doi.org/10.3390/microbiolres12010013 Abstract: The increase in antibacterial resistance (ABR) currently equates in the minds of many antibacterial, bacteria, infection, incentive, AMR, ABR
- [L’IRT BIOASTER, passe l’épreuve de l’exercice « PPI »    ](https://www.bioaster.org/fr/event/lirt-bioaster-passe-lepreuve-de-lexercice-ppi/) - A la demande de la Préfecture, le @SDMIS69 –Service Départemental et Métropolitain d’Incendie et de Secours- conjointement avec la Police Nationale @PoliceNat69, a procédé jeudi 7 janvier à un exercice partiel de Sécurité Civile de type « PPI » pour Plan Particulier d’Intervention, au sein de l’Institut de Recherche Technologique BIOASTER à Lyon, au cœur du biodistrict de Gerland.
- [Xavier Morge est nommé Directeur Général de l’Institut de Recherche Technologique BIOASTER](https://www.bioaster.org/event/xavier-morge-is-appointed-ceo-of-bioaster/) - Xavier Morge a pris ses nouvelles fonctions le 30 novembre dernier et remplace à ce poste Nathalie Garçon.
- [Xavier Morge is appointed CEO of BIOASTER](https://www.bioaster.org/event/xavier-morge-is-appointed-ceo-of-bioaster/) - Xavier Morge took up his new position on November 30th and replaces Nathalie Garçon as BIOASTER’s CEO.
- [I4ID 2020: IMMUNOTHERAPIES & INNOVATIONS FOR INFECTIOUS DISEASES CONGRESS 2020](https://www.bioaster.org/event/i4id-2020-immunotherapies-innovations-for-infectious-diseases-congress-2020/) - In regard to the current situation due to the COVID-19 epidemic and after careful consideration, the organization committee (Bioaster, Lyonbiopôle and MabDesign), with the approval of scientific advisory committee, has decided to digitize the fourth edition of the Immunotherapies & Innovations for Infectious Diseases Congress (I4ID2020), that will be held on December 9-10, 2020 Rest
- [I4ID 2020: IMMUNOTHERAPIES & INNOVATIONS FOR INFECTIOUS DISEASES CONGRESS 2020](https://www.bioaster.org/event/i4id-2020-immunotherapies-innovations-for-infectious-diseases-congress-2020/) - In regard to the current situation due to the COVID-19 epidemic and after careful consideration, the organization committee (Bioaster, Lyonbiopôle and MabDesign), with the approval of scientific advisory committee, has decided to digitize the fourth edition of the Immunotherapies & Innovations for Infectious Diseases Congress (I4ID2020), that will be held on December 9-10, 2020 Rest
- [Novel Antimicrobials & AMR Diagnostics 2019](https://www.bioaster.org/event/novel-antimicrobials-amr-diagnostics-2019/) - BIOASTER will attend the upcoming Novel Antimicrobials and AMR Diagnostics 2019. Come and meet with our partnership team in Berlin on March 14th and 15th 2019 More information : https://amr-conference.com/
- [FIND and BIOASTER collaborate on clinical research](https://www.bioaster.org/event/find-and-bioaster-collaborate-on-clinical-research/) - FIND and BIOASTER collaborate on clinical research to assess duration of immune response in patients with COVID-19.
- [IABS to celebrate 65th Anniversary with a Conference about infectious diseases](https://www.bioaster.org/event/iabs-to-celebrate-65th-anniversary-with-a-conference-about-infectious-diseases/) - L'IABS (Conférence international sur les maladies infectieuses émergentes) célèbre son 65e anniversaire avec une conférence sur les maladies infectieuses.
- [Forum Santé Innovation La tribune, Lyon](https://www.bioaster.org/fr/event/forum-sante-innovation-la-tribune-lyon/) - Découvrez le Forum Santé Innovation - La Tribune le 09 Avril 2020 à Lyon avec Bioaster. Ajoutez l'événement à votre calendrier.
- [IABS to celebrate 65th Anniversary with a Conference about infectious diseases](https://www.bioaster.org/event/iabs-to-celebrate-65th-anniversary-with-a-conference-about-infectious-diseases/) - IABS (International Alliance for Biological Standardization) to celebrate 65th Anniversary with a Conference about infectious diseases.
- [Forum Santé Innovation, La Tribune, Lyon](https://www.bioaster.org/fr/event/forum-sante-innovation-la-tribune-lyon-2/) - Découvrez le Forum Santé Innovation - La Tribune le 24 Septembre 2020 à Lyon avec Bioaster.
- [Forum Santé Innovation, La Tribune, Lyon](https://www.bioaster.org/event/forum-sante-innovation-la-tribune-lyon/) - 24th september 2020, Discover the Health Innovation Forum, La Tribune, Lyon with Bioaster.
- [World Neglected Tropical Diseases Day](https://www.bioaster.org/fr/event/world-neglected-tropical-deseases-day/) - Première Journée mondiale des maladies tropicales négligées afin de sensibiliser sur ces maladies qui touchent plus d'un milliard de personnes.
- [FIND and BIOASTER collaborate on clinical research](https://www.bioaster.org/fr/event/find-and-bioaster-collaborate-on-clinical-research/) - FIND et BIOASTER collaborent à la recherche clinique pour évaluer la durée de la réponse immunitaire chez les patients atteints de COVID-19.
- [Discover our new @BIOASTER publication in Poultry Sciences](https://www.bioaster.org/event/discover-our-new-bioaster-publication-in-poultry-sciences/) - Discover our new @BIOASTER publication in @PoultrySci We are really happy to share our new publication in @PoultrySci. This #Multiomics study, combining #Metabolomics and #Transcriptomics, aims at deciphering the pathways involved in the immune response induced by an immune-stimulant in chickens. This work is part of a collaboration with @Boehringer_AH (a founding member of @Bioaster)
- [EVOTEC AND BIOASTER PARTNER TO BUILD A TECHNOLOGY AND INNOVATION HUB IN LYON](https://www.bioaster.org/event/evotec-and-bioaster-partner-to-build-a-technology-and-innovation-hub-in-lyon/) - To accelerate and strenghen their research capabilities dedicated to fight infectious disease. Evotec SE and the French-based BIOASTER Technological Research Institute today announced that they have entered into a partnership to advance research for infectious diseases The complete press release here.
- [RENCONTREZ-NOUS AUX JOURNEES INTEGRATIVES DE PROTEOMIQUE ET METABOLOMIQUE](https://www.bioaster.org/fr/event/rencontrez-nous-aux-journees-integratives-de-proteomique-et-metabolomique/) - RENCONTREZ-NOUS AUX JOURNEES INTEGRATIVES DE PROTEOMIQUE ET METABOLOMIQUE Jeudi 8 octobre 2020 par visioconférence BIOASTER participera à la troisième édition de la Journée Intégrative de Protéomique et Métabolomique, le 8 octobre 2020, Lyon, FR Dr. Frédéric BEQUET, responsable du pôle Omics à Bioaster, parlera de des intégrations technologiques en Métabolomique et Protéomique pour la recherche
- [BIOASTER intervient à la table ronde Semaine collaborative LYONBIOPOLE 100% digital](https://www.bioaster.org/fr/event/bioaster-intervient-a-la-table-ronde-semaine-collaborative-lyonbiopole-100-digital/) - Dr. Gilles Courtemanche participera à la table ronde 100% digital sur les #maladiesinfectieuses/Europe pendant la semaine colloaborative de @Lyonbiopole. Il rejoindra Stephane Renard, @Evotec et François Vandernesh @CIRI Note agenda: Vendredi 16/10 de 10H à 12h! Informations: http://14e-journee-collaborative.b2match.io [SEMAINE COLLABORATIVE] Stéphane RENARD, Gilles COURTEMANCHE et François VANDERNESH animeront la TR "Essais précliniques alternatifs : des
- [Registration I4ID 2020! Deadline early bird rate extended to October 30th!](https://www.bioaster.org/event/registration-i4id-2020-deadline-early-bird-rate-extended-to-october-30th/) - Register to #I4ID2020 Deadline to Early bird registration has been extended to October 30th! Registration, Program and sponsor information: https://www.i4id.org/ #infectiousdiseases #immunotherapies MabDesign Network Lyonbiopôle
- [MEET US AT THE INTEGRATIVE WORKSHOP ON PROTEOMICS AND METABOLOMICS](https://www.bioaster.org/event/meet-us-at-the-integrative-workshop-on-proteomics-and-metabolomics/) - MEET US AT THE INTEGRATIVE WORKSHOP ON PROTEOMICS AND METABOLOMICS Thursday October 8 2020, by visio conference BIOASTER will participate the 3rd Integrative Workshop on Proteomics and Metabolomics, 08 October 2020, Lyon, FR Dr. Frédéric Béquet, head of Bioaster’s Omics Hub, is a guest speaker and will talk about technological integrations in Metabolomics and Proteomics
- [Meet us at the 1st DxPx – Diagnostics Partnering conference in Dusseldorf on November from 18th to 20th](https://www.bioaster.org/event/meet-us-at-the-1st-dxpx-diagnostics-partnering-conference-in-dusseldorf-on-november-from-18th-to-20th/) - Sara Fröjdö will be present at the 1st DxPx Diagnostics Partnering event as well as at MEDICA the week of November 18th in Dusseldorf, Germany.
- [Venez nous rencontrer lors de la 1ère conférence DxPx - Diagnostics Partnering puis à MEDICA à Düsseldorf du 18 au 20 novembre 2019](https://www.bioaster.org/event/meet-us-at-the-1st-dxpx-diagnostics-partnering-conference-in-dusseldorf-on-november-from-18th-to-20th/) - Venez nous rencontrer lors de la 1ère édition de la conférence DxPx - Diagnostics Partnering à Düsseldorf, Allemagne, le 18 novembre 2019.
- [BIOASTER proud to be part of the 14-partner 10-million€ consortium to identify novel biomarkers and therapeutic targets needed for future precision medicine approaches against sepsis](https://www.bioaster.org/event/bioaster-proud-to-be-part-of-the-14-partner-10-millione-consortium-to-identify-novel-biomarkers-and-therapeutic-targets-needed-for-future-precision-medicine-approaches-against-sepsis/) - BIOASTER est fier de faire partie du consortium de 14 partenaires de 10 millions d'euros pour identifier de nouveaux biomarqueurs et cibles thérapeutiques.
- [Enterome collaborates with BIOASTER Institute](https://www.bioaster.org/event/enterome-collaborates-with-bioaster-institute/) - Enterome collaborates with BIOASTER Institute to provide new insights into mechanisms of potential microbiome-derived cancer immunotherapies
- [Enterome collaborates with BIOASTER Institute](https://www.bioaster.org/event/enterome-collaborates-with-bioaster-institute/) - Enterome collabore avec BIOASTER pour fournir de nouvelles informations sur les mécanismes d'immunothérapies anticancéreuses potentielles dérivées du microbiome
- [BIOASTER proud to be part of the 14-partner 10-million€ consortium to identify novel biomarkers and therapeutic targets needed for future precision medicine approaches against sepsis](https://www.bioaster.org/event/bioaster-proud-to-be-part-of-the-14-partner-10-millione-consortium-to-identify-novel-biomarkers-and-therapeutic-targets-needed-for-future-precision-medicine-approaches-against-sepsis/) - BIOASTER proud to be part of the 14-partner 10-million€ consortium to identify novel biomarkers and therapeutic targets.
- [World Neglected Tropical Diseases Day](https://www.bioaster.org/event/world-neglected-tropical-deseases-day/) - Today, January 30, 2020 is the inaugural World Neglected Tropical diseases Day, whose objective is to raise awareness on these diseases affecting more than one billion people in tropical countries. January 30, 2012, in London, at the initiative of WHO and Bill and Melinda Gates Foundation, the 13 leading pharmaceutical groups, some governments from developed
- [MEET US AT 7th ANNUAL SINGLE CELL ANALYSIS CONGRESS IN LONDON, UK](https://www.bioaster.org/event/meet-us-at-7th-annual-single-cell-analysis-congress-in-london-uk/) - Microfluidics BIOASTER will be attending the 7th Annual Single Cell Analysis Congress 07 – 08 November 2019, London, UK Dr. Yacine Bounab (Biological systems & Advanced Optics Engineering Unit) will present the droplet microfluidic technology for single cell phenotyping developed at BIOASTER’s Biological Microsytems & Advanced Optics engineering group. More information on https://www.oxfordglobal.co.uk/singlecell-congress/
- [PEGS Europe congress](https://www.bioaster.org/event/meet-bioaster-at-pegs-europe-congress-from-november-12th-to-16th-2018-lisbon-portugal/) - Meet BIOASTER at PEGS Europe congress from November 12th to 16th, 2018 @Lisbon, Portugal
- [Keystone Symposia](https://www.bioaster.org/event/participation-keystone-conference-intitled-microbiome-chemical-mechanisms-and-biological-consequences-2019/) - BIOASTER will participate to the next Keystone conference intitled 'Microbiome: Chemical Mechanisms and Biological Consequences' on March 10 to 14 at Montréal.
- [Single-Molecule sensors and nanoSystems International Conference - Munich; 3-5 April 2019](https://www.bioaster.org/event/single-molecule-sensors-and-nanosystems-international-conference-munich-3-5-april-2019/) - BIOASTER participated to the Single-Molecule sensors and nanoSystems International Conference which was held in Munich, 3-5 April 2019. Dr. Yacine Bounab presented the droplet-based microfluidic technology for single-cell phenotyping, developed at Bioaster’s Biological Microsytems & Advanced Optics engineering unit.
- [ASM Microbe 2019- San Francisco, USA](https://www.bioaster.org/event/asm-microbe-2019-san-francisco-usa/) - Meet us at the next ASM congress (American Society for Microbiology) held from June 20th to 24th organized at San Francisco, USA. Program available here: https://eventpilotadmin.com/web/page.php?page=Home&project=ASM19
- [General meeting - EU project TRANSVAC 2; May 14th & 15th, 2019](https://www.bioaster.org/event/general-meeting-eu-project-transvac-2-may-14th-15th-2019/) - The general meeting of TRANSAC 2 EU's project will be held @BIOASTER on May 14th & 15th, 2019. More information about the EU project: http://www.euvaccine.eu/portfolio/project-index/transvac2
- [BIOASTER @ World Vaccine congress 2019](https://www.bioaster.org/event/bioaster-world-vaccine-congress-2019/) - BIOASTER will participe to the next World Vaccine 2019 congress at Washington DC, USA from April 14th to 17th, 2019. Dr. Nathalie GARCON, BIOASTER CEO&CSO will chair a round table about 'Safety evaluation of vaccines: from now to tomorrow, new approaches and technologies?' on April 15th.
- [BIOASTER at ECCMID congress 2019](https://www.bioaster.org/event/bioaster-at-eccmid-congress-2019/) - BIOASTER will be in Amsterdam for ECCMID on April 14th and 15th to follow and discuss the future of microbiology and infectious diseases. The diagnostic team would be happy to meet you in Amsterdam!
- [Kick off Project IMI Value-DX](https://www.bioaster.org/event/kick-off-project-imi-value-dx/) - BIOASTER teams are currently in Madrid for the kick-off meeting of the Value-Dx project. We are proud to be part of such a consortium, funded by the European Union and the Innovative Medicines Initiative, teaming up with industry and academia to fight antimicrobial resistance.

## Technologies designed by BIOASTER

- [DROPCELL](https://www.bioaster.org/technology/dropcell/) - Results DROPCELL technology has been reported in various publications and patented by BIOASTER. The reported application focuses on the study of TNFa (tumor necrosis factor) secreting profile of monocytes when exposed to Lipopolysaccharides (LPS). A key feature of the droplet-based immunoassay lies in the use of paramagnetic nanoparticles where capture anti-TNFa antibodies are immobilized. Briefly,
- [HoloMoA](https://www.bioaster.org/technology/holomoa/) - Advantage Simple technology requiring no specialist knowledge once databases completed Label-free technology based on digital inline holographic microscopy • Live bacteria, so time-course of measurements possible Time-frame for measurement: 0 to >24 h, typically 2 h Medium-throughput, semi-automated platform Simpler, faster, less expensive than classical methods Provide the potential MoA during preclinical development with good
- [HoloMoA](https://www.bioaster.org/technology/holomoa/) - Advantage Simple technology requiring no specialist knowledge once databases completed Label-free technology based on digital inline holographic microscopy • Live bacteria, so time-course of measurements possible Time-frame for measurement: 0 to >24 h, typically 2 h Medium-throughput, semi-automated platform Simpler, faster, less expensive than classical methods Provide the potential MoA during preclinical development with good
- [COLPLEX](https://www.bioaster.org/technology/colplex/) - Evidence / Results Based on the internal proof-of-concept, BIOASTER has investigated a more realistic application of its technology. through funding from the BMGF (Bill & Melinda Gates Fundation), BIOASTER is currently developing a first 3plex LFA immuno-assay and also demonstrate the feasibility of using the technology in a molecular LFA test. At this stage and
- [COLPLEX](https://www.bioaster.org/technology/colplex/) - Evidence / Results Based on the internal proof-of-concept, BIOASTER has investigated a more realistic application of its technology. through funding from the BMGF (Bill & Melinda Gates Fundation), BIOASTER is currently developing a first 3plex LFA immuno-assay and also demonstrate the feasibility of using the technology in a molecular LFA test. At this stage and
- [Noso Infections](https://www.bioaster.org/technology/noso-infections/) - Evidence / Results BIOASTER has achieved the following results: Bioluminescent Carbapenem sensitive strain of A. baumannii that is validated in vitro and in vivo Bioluminescent Carbapenem resistant strain of A. baumannii that is validated in vitro and in vivo Improve the sensitivity of in vivo imaging to follow drug efficacy below the current limit of
- [Noso Infections](https://www.bioaster.org/technology/noso-infections/) - Evidence / Results BIOASTER has achieved the following results: Bioluminescent Carbapenem sensitive strain of A. baumannii that is validated in vitro and in vivo Bioluminescent Carbapenem resistant strain of A. baumannii that is validated in vitro and in vivo Improve the sensitivity of in vivo imaging to follow drug efficacy below the current limit of
- [ADSORB](https://www.bioaster.org/technology/adsorb/) - Evidence / Results a novel on chip technological method (one step protocol) to integrate a hydrogel as diffusive membrane a three parallel microchannel device was designed, fabricated and tested static and dynamic diffusion of a fluorescent dye was demonstrated without biofilm the different distance of the lateral microchannels could be used to deliver drugs of
- [ANOXIC PLATFORM](https://www.bioaster.org/technology/anoxic-platform/) - Advantages The advantage is for companies wishing to isolate microorganisms of interest from complex ecosystems (e.g. human and animal health biotech, environment and food industry). The high sensitivity of the system allow to sort and isolate very low abundant bacteria (as low as 0.02% of relative abundance). Targeted cell-sorting under anaerobic conditions is a promising
- [ANOXIC PLATFORM](https://www.bioaster.org/technology/anoxic-platform/) - Advantages The advantage is for companies wishing to isolate microorganisms of interest from complex ecosystems (e.g. human and animal health biotech, environment and food industry). The high sensitivity of the system allow to sort and isolate very low abundant bacteria (as low as 0.02% of relative abundance). Targeted cell-sorting under anaerobic conditions is a promising
- [BLOOD-ON-CHIP](https://www.bioaster.org/technology/blood-on-chip/) - Evidence / Results We developed a PDMS-glass microfluidic device that spatially organizes a co- culture consisting of primary human skeletal and endothelial cells mimicking the interface between blood flow and a microtissue. An injectable biodegradable, a natural hydrogel, is introduced in-between both circulation and microtissue compartments to maintain tissue integrity. To simulate in vivo-like conditions,
- [BLOOD-ON-CHIP](https://www.bioaster.org/technology/blood-on-chip/) - Evidence / Results We developed a PDMS-glass microfluidic device that spatially organizes a co- culture consisting of primary human skeletal and endothelial cells mimicking the interface between blood flow and a microtissue. An injectable biodegradable, a natural hydrogel, is introduced in-between both circulation and microtissue compartments to maintain tissue integrity. To simulate in vivo-like conditions,
- [GNOTOMICE](https://www.bioaster.org/technology/gnotomice/) - Advantages GM15 mouse model benefit the scientific and industrial community by providing in vivo experimental evidence sustaining the causal link between a given microbiota and health or disease. In addition, the GM15 model offers exciting perspectives for preclinical research focusing on drug-host-microbes interactions to evaluate antimicrobial resistance and the impact of drugs on commensals and
- [GNOTOMICE](https://www.bioaster.org/technology/gnotomice/) - Advantages GM15 mouse model benefit the scientific and industrial community by providing in vivo experimental evidence sustaining the causal link between a given microbiota and health or disease. In addition, the GM15 model offers exciting perspectives for preclinical research focusing on drug-host-microbes interactions to evaluate antimicrobial resistance and the impact of drugs on commensals and

## Events

- [BIOASTER will be @ Medlab Middle East | Medical Expo & Conference | Dubai 2025](https://www.bioaster.org/event/bioaster-will-be-medlab-middle-east-medical-expo-conference-dubai-2025/)
- [Dr Benoit Levast will present: "Exfoliome, a proxy of the gut mucosal immune response"](https://www.bioaster.org/event/dr-benoit-levast-will-present-exfoliome-a-proxy-of-the-gut-mucosal-immune-response/)
- [BIOASTER is invited to present its technologies at AI-TECHNOLOGY-CROSSROADS SYMPOSIUM | Research -](https://www.bioaster.org/event/bioaster-is-invited-to-present-its-technologies-at-ai-technology-crossroads-symposium-research/)
- [BIOASTER is waiting for you at I4ID 2024 - November 27-28](https://www.bioaster.org/event/bioaster-is-waiting-for-you-at-i4id-2024-november-27-28/)
- [BIOASTER will present at American Society of Tropical Medicine and Hygiene (ASTMH) 13 – 17 November, 2 posters:](https://www.bioaster.org/event/bioaster-will-present-at-american-society-of-tropical-medicine-and-hygiene-astmh-13-17-november-2-posters/)
- [BIOASTER will be at MEDICA - Leading International Trade Fair Düsseldorf, Germany, 11-14 November! https://lnkd.in/ga2u_rwn](https://www.bioaster.org/event/bioaster-will-be-at-medica-leading-international-trade-fair-dusseldorf-germany-11-14-november-https-lnkd-in-ga2u_rwn/)
- [Dr @cyrilguyard, CSO @BIOASTER will be speaker @ISV : Congress – The International Society
for Vaccines (isv-online.org)](https://www.bioaster.org/event/dr-cyrilguyard-cso-bioaster-will-be-speaker-isv-congress-the-international-societyfor-vaccines-isv-online-org/)
- [BIOASTER is proud to contribute to the AMR Accelerator programme](https://www.bioaster.org/event/bioaster-is-proud-to-contribute-to-the-amr-accelerator-programme/)
- [BIOASTER au SIDO Lyon pour parler IA](https://www.bioaster.org/event/bioaster-au-sido-lyon-pour-parler-ia/)
- [ESCMID Conference, Porto
 17-20 September, Dr Abdessalem REKIKI BIOASTER will present a poster](https://www.bioaster.org/event/escmid-conference-porto-17-20-september-dr-abdessalem-rekiki-bioaster-will-present-a-poster/)
- [BIOASTER will be at ESCMID: ESCMID ASM Conference September17-20!](https://www.bioaster.org/event/bioaster-will-be-at-escmid-escmid-asm-conference-september17-20/)
- [BIOASTER Talk @ADTCA](https://www.bioaster.org/event/bioaster-talk-adtca/)
- [Best Poster Awards](https://www.bioaster.org/event/best-poster-awards/)
- [Xavier MORGE, CEO BIOASTER au Healtech Acceleration Summit](https://www.bioaster.org/event/xavier-morge-ceo-bioaster-au-healtech-acceleration-summit/)
- [BIOASTER is proud to announce that it has obtained Olink Proteomics certification](https://www.bioaster.org/event/bioaster-is-proud-to-announce-that-it-has-obtained-olink-proteomics-certification/)
- [Le 27 juin à Lyon, @healthtech Acceleration Summit](https://www.bioaster.org/event/le-27-juin-a-lyon-healthtech-acceleration-summit/)
- [BIOASTER CSO Cyril Guyard conference @CIRC @IARC](https://www.bioaster.org/event/bioaster-cso-cyril-guyard-conference-circ-iarc/)
- [ADAY@BIOASTER#5](https://www.bioaster.org/event/adaybioaster5/)
- [BIOASTER @probiotic-conference June 18](https://www.bioaster.org/event/bioaster-probiotic-conference-june-18/)
- [BIOASTER participe à la JNBB le 5 juillet 2024 #bioproduction](https://www.bioaster.org/event/bioaster-participe-a-la-jnbb-le-5-juillet-2024-bioproduction/)
- [BIOASTER @healthtech Acceleration Summit](https://www.bioaster.org/event/bioaster-healthtech-acceleration-summit/)

## Categories

- [Live](https://www.bioaster.org/category/live/)
- [Live](https://www.bioaster.org/category/live/)
- [News](https://www.bioaster.org/category/live/news/)
- [Latest news](https://www.bioaster.org/category/live/latest-news/)
- [Zoom](https://www.bioaster.org/category/live/zoom/)
- [BIOASTER events](https://www.bioaster.org/category/live/bioaster-events/)
- [Collaborative days](https://www.bioaster.org/category/live/collaborative-days/)
- [Congress/conferences](https://www.bioaster.org/category/live/congress-conferences/)
- [EU projects](https://www.bioaster.org/category/live/eu-projects/)
- [Events @BIOASTER](https://www.bioaster.org/category/live/events-bioaster/)
- [Corporate BIOASTER](https://www.bioaster.org/category/live/corporate-bioaster/)
- [Press releases](https://www.bioaster.org/category/live/press-releases/)
- [Scientific releases](https://www.bioaster.org/category/live/scientific-releases/)
- [Videos](https://www.bioaster.org/category/live/videos/)
- [Visits](https://www.bioaster.org/category/live/visits/)
- [BIOASTER technologies](https://www.bioaster.org/category/live/bioaster-technologies/)
- [Projects](https://www.bioaster.org/category/live/projects/)
- [BIOASTER partners](https://www.bioaster.org/category/live/bioaster-partners/)
- [BIOASTER événements](https://www.bioaster.org/category/live/bioaster-events/)
- [BIOASTER partenaires](https://www.bioaster.org/category/live/bioaster-partners/)
- [BIOASTER technologies](https://www.bioaster.org/category/live/bioaster-technologies/)
- [Journées collaboratives](https://www.bioaster.org/category/live/collaborative-days/)
- [Congrès / conférences](https://www.bioaster.org/category/live/congress-conferences/)
- [L'institut BIOASTER](https://www.bioaster.org/category/live/corporate-bioaster/)
- [Projets européens](https://www.bioaster.org/category/live/eu-projects/)
- [Événements @BIOASTER](https://www.bioaster.org/category/live/events-bioaster/)
- [Dernières actualités](https://www.bioaster.org/category/live/latest-news/)
- [Actualités](https://www.bioaster.org/category/live/news/)
- [Communiqués de presse](https://www.bioaster.org/category/live/press-releases/)
- [Projets](https://www.bioaster.org/category/live/projects/)
- [Communiqués scientifiques](https://www.bioaster.org/category/live/scientific-releases/)
- [Vidéos](https://www.bioaster.org/category/live/videos/)
- [Zoom](https://www.bioaster.org/category/live/zoom/)

## Tags

- [Multiomics](https://www.bioaster.org/tag/multiomics-2/)
- [avian](https://www.bioaster.org/tag/avian-2/)
- [ImmuneResponse](https://www.bioaster.org/tag/immuneresponse-2/)
- [Metabolomics](https://www.bioaster.org/tag/metabolomics-2/)
- [Transcriptomics](https://www.bioaster.org/tag/transcriptomics-2/)
- [ImmuneResponse](https://www.bioaster.org/tag/immuneresponse-2/)
- [Metabolomics](https://www.bioaster.org/tag/metabolomics-2/)
- [Gencovery](https://www.bioaster.org/tag/gencovery-2/)
- [startup](https://www.bioaster.org/tag/startup-2/)
- [Gencovery](https://www.bioaster.org/tag/gencovery-2/)
- [startup](https://www.bioaster.org/tag/startup-2/)
- [microbiota](https://www.bioaster.org/tag/microbiota/)
- [Gnotobiotic](https://www.bioaster.org/tag/gnotobiotic/)
- [microbiota](https://www.bioaster.org/tag/microbiota/)
- [preclinical](https://www.bioaster.org/tag/preclinical/)
- [SARS-CoV-2](https://www.bioaster.org/tag/sars-cov-2/)
- [phenotip screening](https://www.bioaster.org/tag/phenotip-screening/)
- [COVID19](https://www.bioaster.org/tag/covid19/)
- [COVID19](https://www.bioaster.org/tag/covid19/)
- [phenotip screening](https://www.bioaster.org/tag/phenotip-screening/)
- [SARS-CoV-2](https://www.bioaster.org/tag/sars-cov-2/)
- [omics](https://www.bioaster.org/tag/omics/)
- [conference](https://www.bioaster.org/tag/conference/)
- [omics](https://www.bioaster.org/tag/omics/)
- [immunotherapies](https://www.bioaster.org/tag/immunotherapies/)
- [infectiousdiseases](https://www.bioaster.org/tag/infectiousdiseases/)
- [microbiology](https://www.bioaster.org/tag/microbiology/)
- [events](https://www.bioaster.org/tag/events/)
- [immunotherapies](https://www.bioaster.org/tag/immunotherapies/)
- [infectiousdiseases](https://www.bioaster.org/tag/infectiousdiseases/)
- [microbiology](https://www.bioaster.org/tag/microbiology/)
- [PPI](https://www.bioaster.org/fr/tag/ppi/)
- [Exercice](https://www.bioaster.org/fr/tag/exercice/)
- [intervention](https://www.bioaster.org/fr/tag/intervention/)
- [antibacterial](https://www.bioaster.org/tag/antibacterial/)
- [bacteria](https://www.bioaster.org/tag/bacteria/)
- [infection](https://www.bioaster.org/tag/infection/)
- [incentive](https://www.bioaster.org/tag/incentive/)
- [AMR](https://www.bioaster.org/tag/amr/)
- [ABR](https://www.bioaster.org/tag/abr/)
- [AMI](https://www.bioaster.org/fr/tag/ami/)
- [maladiesinfectieuses](https://www.bioaster.org/fr/tag/maladiesinfectieuses/)
- [joinus](https://www.bioaster.org/fr/tag/joinus/)
- [BPIFrance](https://www.bioaster.org/fr/tag/bpifrance/)
- [SGPI](https://www.bioaster.org/fr/tag/sgpi/)
- [collaboration](https://www.bioaster.org/tag/collaboration/)
- [Microbiote](https://www.bioaster.org/fr/tag/microbiote-fr/)
- [collaboration](https://www.bioaster.org/fr/tag/collaboration-fr/)
- [CP](https://www.bioaster.org/fr/tag/cp/)
- [communiqué presse](https://www.bioaster.org/fr/tag/communique-presse/)
- [Bioaster](https://www.bioaster.org/fr/tag/bioaster/)
- [APM](https://www.bioaster.org/fr/tag/apm/)
- [Probiotic](https://www.bioaster.org/tag/probiotic/)
- [Probiotic](https://www.bioaster.org/tag/probiotic/)
- [Micrbiota](https://www.bioaster.org/tag/micrbiota/)
- [microbiome](https://www.bioaster.org/tag/microbiome/)
- [collaborative projects](https://www.bioaster.org/tag/collaborative-projects/)
- [Micrbiote](https://www.bioaster.org/tag/micrbiota/)
- [microbiome](https://www.bioaster.org/tag/microbiome/)
- [Projets collaboratifs](https://www.bioaster.org/tag/collaborative-projects/)
- [antimicrobial](https://www.bioaster.org/tag/antimicrobial/)
- [call](https://www.bioaster.org/tag/call/)
- [opportunity](https://www.bioaster.org/tag/opportunity/)
- [antibiotic](https://www.bioaster.org/tag/antibiotic/)
- [antimicrobial](https://www.bioaster.org/tag/antimicrobial/)
- [call](https://www.bioaster.org/tag/call/)
- [opportunity](https://www.bioaster.org/tag/opportunity/)
- [antibiotic](https://www.bioaster.org/tag/antibiotic/)
- [Bioassays](https://www.bioaster.org/tag/bioassays/)
- [microsystems](https://www.bioaster.org/tag/microsystems/)
- [optical](https://www.bioaster.org/tag/optical/)
- [ELIS](https://www.bioaster.org/tag/elis/)
- [LFA](https://www.bioaster.org/tag/lfa/)
- [microfluidics](https://www.bioaster.org/tag/microfluidics/)
- [droplet](https://www.bioaster.org/tag/droplet/)
- [immunology](https://www.bioaster.org/tag/immunology/)
- [biomarkers](https://www.bioaster.org/tag/biomarkers/)
- [microfluidique](https://www.bioaster.org/tag/microfluidics/)
- [gouttes](https://www.bioaster.org/tag/droplet/)
- [immunologie](https://www.bioaster.org/tag/immunology/)
- [biomarqueurs](https://www.bioaster.org/tag/biomarkers/)
- [microbiologie](https://www.bioaster.org/tag/microbiologie-2/)
- [cytométrie en flux](https://www.bioaster.org/tag/cytometrie-en-flux-2/)
- [culturomique](https://www.bioaster.org/tag/culturomique-2/)
- [microbes](https://www.bioaster.org/tag/microbes-2/)
- [microbes](https://www.bioaster.org/tag/microbes-2/)
- [culturomics](https://www.bioaster.org/tag/culturomics/)
- [cytometry](https://www.bioaster.org/tag/cytometry/)
- [Antibioresistance](https://www.bioaster.org/tag/antibioresistance/)
- [antibiotics](https://www.bioaster.org/tag/antibiotics/)
- [bacteremia](https://www.bioaster.org/tag/bacteremia/)
- [bacteriophages](https://www.bioaster.org/tag/bacteriophages/)
- [bloodinfections](https://www.bioaster.org/tag/bloodinfections/)
- [ecoli](https://www.bioaster.org/tag/ecoli/)
- [innovation](https://www.bioaster.org/tag/innovation/)
- [phages](https://www.bioaster.org/tag/phages/)
- [phagetherapy](https://www.bioaster.org/tag/phagetherapy/)
- [pharma](https://www.bioaster.org/tag/pharma/)
- [bloodonchip](https://www.bioaster.org/tag/bloodonchip/)
- [Blood-on-chip](https://www.bioaster.org/tag/blood-on-chip/)
- [diagnostic](https://www.bioaster.org/tag/diagnostic/)
- [REALISM](https://www.bioaster.org/tag/realism/)
- [intensive care](https://www.bioaster.org/tag/intensive-care/)
- [vaccines](https://www.bioaster.org/tag/vaccines/)
- [COVID](https://www.bioaster.org/tag/covid/)
- [Lunginfection](https://www.bioaster.org/tag/lunginfection/)
- [biotherapeutic](https://www.bioaster.org/tag/biotherapeutic/)
- [targetedculturomics](https://www.bioaster.org/tag/targetedculturomics/)
- [antibodies](https://www.bioaster.org/tag/antibodies/)
- [flowcytometry](https://www.bioaster.org/tag/flowcytometry/)
- [congress](https://www.bioaster.org/tag/congress/)
- [innovations](https://www.bioaster.org/tag/innovations/)
- [diagnostics](https://www.bioaster.org/tag/diagnostics/)
- [antimicrobials](https://www.bioaster.org/tag/antimicrobials/)
- [AMR](https://www.bioaster.org/tag/amr/)
- [antibiotics](https://www.bioaster.org/tag/antibiotics/)
- [antimicrobials](https://www.bioaster.org/tag/antimicrobials/)
- [Spike Protein](https://www.bioaster.org/tag/spike-protein/)
- [infection](https://www.bioaster.org/tag/infection/)
- [Spike Protein](https://www.bioaster.org/tag/spike-protein/)
- [vaccines](https://www.bioaster.org/tag/vaccines/)
- [massspectrometry](https://www.bioaster.org/tag/massspectrometry/)
- [Metabolomic](https://www.bioaster.org/tag/metabolomic/)
- [Proteomics](https://www.bioaster.org/tag/proteomics/)
- [Equipement](https://www.bioaster.org/tag/equipement/)
- [Equipement](https://www.bioaster.org/tag/equipement/)
- [massspectrometry](https://www.bioaster.org/tag/massspectrometry/)
- [Metabolomic](https://www.bioaster.org/tag/metabolomic/)
- [Proteomics](https://www.bioaster.org/tag/proteomics/)
- [Antibioresistance](https://www.bioaster.org/tag/antibioresistance/)
- [Assay](https://www.bioaster.org/tag/assay/)
- [Assay](https://www.bioaster.org/tag/assay/)
- [diagnostics](https://www.bioaster.org/tag/diagnostics/)
- [immune response](https://www.bioaster.org/tag/immune-response/)
- [viral infection](https://www.bioaster.org/tag/viral-infection/)
- [coronaviruses](https://www.bioaster.org/tag/coronaviruses/)
- [pandemic strains](https://www.bioaster.org/tag/pandemic-strains/)
- [influenza](https://www.bioaster.org/tag/influenza/)
- [coronaviruses](https://www.bioaster.org/tag/coronaviruses/)
- [immune response](https://www.bioaster.org/tag/immune-response/)
- [influenza](https://www.bioaster.org/tag/influenza/)
- [pandemic strains](https://www.bioaster.org/tag/pandemic-strains/)
- [viral infection](https://www.bioaster.org/tag/viral-infection/)
- [biocrates](https://www.bioaster.org/tag/biocrates-2/)
- [biocrates](https://www.bioaster.org/tag/biocrates-2/)
- [NGS](https://www.bioaster.org/tag/ngs/)
- [Nannopore](https://www.bioaster.org/tag/nannopore/)
- [Genomics](https://www.bioaster.org/tag/genomics/)
- [health](https://www.bioaster.org/tag/health/)
- [research](https://www.bioaster.org/tag/research/)
- [Genomics](https://www.bioaster.org/tag/genomics/)
- [health](https://www.bioaster.org/tag/health/)
- [innovation](https://www.bioaster.org/tag/innovation/)
- [Nannopore](https://www.bioaster.org/tag/nannopore/)
- [NGS](https://www.bioaster.org/tag/ngs/)
- [research](https://www.bioaster.org/tag/research/)
- [article](https://www.bioaster.org/tag/article-2/)

## Categories

- [Press Releases](https://www.bioaster.org/download-category/press-releases/)
- [Technologies designed by Bioaster](https://www.bioaster.org/download-category/technologies-designed-by-bioaster/)
- [Fields of application](https://www.bioaster.org/download-category/fields-of-application/)
- [Technological units](https://www.bioaster.org/download-category/technological-units/)
- [Collaborative Project Examples](https://www.bioaster.org/download-category/collaborative-project-examples/)

## Tags

- [Assay](https://www.bioaster.org/document-tag/assay/)
- [collaboration](https://www.bioaster.org/document-tag/collaboration/)
- [molecular](https://www.bioaster.org/document-tag/molecular/)
- [diagnostic](https://www.bioaster.org/document-tag/diagnostic/)

## Event Categories

- [Conference/congress](https://www.bioaster.org/events/category/conference-congress/)
- [Conférence/congrès](https://www.bioaster.org/events/category/conference-congress/)
- [News](https://www.bioaster.org/events/category/news/)
- [Press release](https://www.bioaster.org/events/category/press-release/)
- [Actualités](https://www.bioaster.org/events/category/news/)
- [Communiqué](https://www.bioaster.org/events/category/press-release/)
- [Latest news](https://www.bioaster.org/events/category/latest-news/)
- [Zoom](https://www.bioaster.org/events/category/zoom/)
- [Dernières actualités](https://www.bioaster.org/events/category/latest-news/)
- [Zoom](https://www.bioaster.org/events/category/zoom/)